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Lung cancer is the leading cause of cancer related deaths and is responsible for 
over one million deaths worldwide each year. While it is widely acknowledged that 
angiogenesis plays an integral role in tumor growth, and therapeutic approaches have 
been taken to inhibit angiogenesis, clinical results have been unexceptional at best. 
Current research models discount the dual lung circulations that create a unique growth 
environment for tumors, by utilizing subcutaneous xenograft models that have little 
relevance to the lung, or orthotopic models in mice, which lack a bronchial circulation. In 
an effort to bridge the gap between animal models of questionable relevance, and clinical 
trials, we developed an orthotopic model of lung cancer in nude rats to examine the role 
of the bronchial artery in tumor growth. Using two methods of quantifying tumor 
perfusion in vivo we measured an increase in bronchial artery perfusion quantified by 
fluorescent microsphere injection (206%) and HRCT scan (276%), that paralleled the 
growth in tumor volume, while pulmonary perfusion remained unchanged. When ablating 
the bronchial artery after the initiation of tumor growth, we observed a 76% decrease in 
final tumor volumes at 4 weeks post ablation. In an effort to examine the innate 
differences in the pulmonary and bronchial circulations’ response to tumor growth, 
primary endothelial cell lines were isolated from the bronchial artery, pulmonary artery, 
and pulmonary microvasculature of nude rats for the determination of their angiogenic 
potential. Bronchial artery endothelial cells uniquely showed increased proliferation, tube 
formation, and chemotaxis when exposed to angiogenic stimuli (VEGF, CINC-3, 
Adenocarcinoma Supernatant).  We conclude that the pulmonary circulation initially 
sustains lung tumor establishment. As a tumor increases in size it is the bronchial 
iii 
 
circulation that proliferates to sustain tumor growth beyond the point at which a tumor 
can be supported by the pulmonary circulation alone. The increased angiogenic potential 
of bronchial artery endothelial cells, suggests innate differences between lung 
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Lung cancer is the leading cause of cancer related deaths and 220,000 new cases 
will be diagnosed in the United States this year alone, taking more lives than colon, 
breast, and pancreatic cancer combined (1).  Lung cancer will have a significant impact 
on public health in the economic burden associated with lost productivity and the costs of 
illness and long-term therapy. Many successful public health interventions have been 
implemented with the education of the dangers of cigarette smoking, and assessing 
cancer risks from environmental exposures, however the economic burden will only 
continue to worsen as the population ages and the incidence of disease increases.  
Challenges in early detection of lung cancer, and the aggressive nature of the disease 
result in only 1 of 10 patients living beyond 3 years after diagnosis (1, 2). The high rate 
of disease prevalence and dismal prognosis highlight the need for continued research 
efforts, and in 2016, 362 million dollars from the NIH will go towards studying disease 
prevention, diagnosis, and treatment of lung cancer (3). Over the last century great strides 
have been made in understanding the pathology and mechanisms of lung cancer, 
coinciding with improved treatments and novel therapy approaches, however survival 
rates highlight the essential need for further research. 
 
1.1 Histological Classifications of Lung Cancer 
 
Increased specificity in the classification of lung tumor subtypes and their 
pathologies has resulted in more directed treatment options.  Originally platinum-based 
chemotherapy was generally the first-line therapy until it was observed that patients 
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responded differently to treatment based on their specific tumor’s molecular profile (4). 
Since then great efforts have been made to better align classification of lung cancer 
subpopulations, and in 2011 the International Association for the Study of Lung Cancer, 
the American Thoracic Society, and the European Respiratory Society collectively 
published international multi-disciplinary classifications specific to lung 
adenocarcinomas (5). 
Lung cancer can be classified into three populations; Small Cell Lung Cancer, 
SCLC, (10-15% of cases), Non-Small Cell Lung Cancer, NSCLC, (85% of cases), and 
Lung Carcinoid Tumor (less than 5% of cases).  NSCLC, the most prevalent diagnosis, is 
defined by any malignant epithelial lung tumor lacking a small cell component. NSCLC 
can be further sub-classified into three specific histological subtypes; adenocarcinomas, 
large cell carcinomas, and squamous cell carcinomas (5, 6).  Classifications are based on 
tumor location and histological appearance and can be influenced by race, gender and 
environmental exposure (7).    
Adenocarcinomas are the most common histological subtype of lung cancer 
making up more than half of lung cancer cases (7).  They can be defined as a malignant 
epithelial neoplasm with gland formation and are typically found in the lung periphery. 
The degree of gland formation will also dictate if an adenocarcinoma is well, moderately, 
or poorly differentiated. In well-differentiated tumors, glandular structures are easily 
detected by column like epithelium and mucus production. Adenocarcinomas are further 
divided into bronchioalveolar carcinomas, mucinuous carcinomas, and papillary 
carcinomas. Bronchioalveolar carcinomas are characterized by their lepidic pattern where 
cells line the alveolar walls and appear to replace the normal epithelial lining of airspaces 
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without destruction to the basic lung architecture. Mucinuous carcinomas are usually 
detected by pooling of mucinous material accompanied by destruction of underlying lung 
architecture. Papillary carcinomas can be characterized by their complex papillary 
infoldings and necrotic regions of the alveolar lumen are frequently observed.  Because 
adenocarcinomas are the most common diagnosis, and can be very well differentiated 
tumors, great lengths have been taken to standardize characterization of these tumors (8).  
In contrast to adenocarcinomas, squamous cell carcinomas arise centrally within 
the main airways invading into the airway wall and lumen often times leading to airway 
obstruction. These cancer cells have a flattened and stratified appearance and are 
characterized by intracellular bridging and keratinization.  When a poorly differentiated 
tumor lacks the defining features of an adenocarcinoma or squamous cell carcinoma, by 
exclusion it is usually categorized as a large cell carcinoma (5). Characterizing the lung 
tumor by these distinct histological patterns is the critical first step in designing a cancer 
therapy plan.  
1.2 Original Treatments for Non-Small Cell Lung Cancer 
In the 1980’s, cisplatin and carboplatin were studied as treatment options for 
NSCLC.  This work provided evidence that platinum-based chemotherapy increased 
survival in patients with response rates from 15-25% (9).  When possible, surgery was the 
first option if the disease was localized and had only progressed to stage I or II, but 
survival rates after surgery were still less than 35% (10).  In 2001, the “gold-standard” in 
treatment for patients with inoperable lung tumors was radiotherapy showing 5-year 
survival ranging anywhere from 0-45% (11). Studies examining chemotherapy coupled 
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with radiation therapy failed to show significant improvements with 5-year survival of 
patients less than 15% (12, 13).  Because of severe toxicity of platinum-based drugs, and 
considerable low response and survival rates, treatment options for NSCLC stalled with 
all patients receiving the same therapy regardless of histological subtype.  It was not until 
2004 that it was recognized that tumor genotype was an important factor in a tumor’s 
response to therapy (14).  
Correctly identifying the histological subtype of NSCLC was advantageous for 
selecting the most direct treatment options. Green and colleagues highlighted the 
importance of subtype specific treatments by showing SCLC had the most favorable 
response to cyclophosphamide, and squamous cell carcinomas were more sensitive to 
nitrogen mustard than other histological subtypes (15). Molecular differences in tumor 
subtypes dictated the efficacy of the chemotherapy agent pemetrexed and the anti-
angiogenic therapy bevacizumab to be effective in non-squamous histologies (16).  
Because subtypes of NSCLC responded differently to drug therapies it could be 
concluded that lung tumors not only differed in their origin and histology, but that 
molecular differences between pathological subtypes could also affect treatment 
responses. Traditionally, a distinction between SCLC and NSCLC dictated clinical 
treatment options.  However, this limited observation was no longer considered sufficient 
and a more advanced classification of the NSCLC subtypes was necessary.  
 





Incorporating molecular testing after histological identification provided a new 
approach to lung cancer therapy through the ability to target gene mutations that drove 
tumorigenesis specific to each patient. Molecular testing determined KRAS (Kristen Rat 
Sarcoma Viral Oncogene), EGFR (Epidermal Growth Factor Receptor) and ALK 
(Anaplastic Lymphoma Kinase) mutations make up 32%, 23%, and 3% of gene 
mutations observed in NSCLC (17, 18).  Mutations to these genes result in increased 
tyrosine kinase activity, making drugs that inhibit tyrosine kinase activity ideal 
therapeutic options.  Currently, after determining the histological subtype and the 
presence of an EGFR or ALK mutation, specific treatment protocols are followed. A 
NSCLC tumor will be further categorized as squamous or non-squamous. If a patient has 
a squamous cell carcinoma tumor, platinum-based chemotherapy is the first-line 
treatment option. If the tumor is a non-squamous cell carcinoma, such as an 
adenocarcinoma or a large cell carcinoma, detection of an EGFR or ALK mutation will 
dictate which first-line treatment is selected.  Erlotinib or crizotinib would be selected for 
a first-line treatment in patients with EGFR and ALK mutations respectively (14).  
Tyrosine kinase inhibitors target the intracellular kinase domain of EGFR and 
have been shown to be effective for the treatment of advanced-stage NSCLC with 
increased benefits compared to traditional platinum-based chemotherapy. Despite the 
initial favorable response rates and overall disease-control rates with use of Tyrosine 
kinase inhibitors specific for EGFR and ALK mutations, overall improvement in survival 
has not been reported (14).  Classifying histological subtypes of lung cancer, coupled 
with genotyping each subtype has only modestly improved therapy options.  However, 
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the lack of significantly improved outcomes highlights the need for novel therapeutic 
approaches.   
1.4 Targeting Angiogenesis in Non-Small Cell Lung Cancer 
 
Angiogenesis is defined as the growth of new vessels from existing vessels and is 
an attractive target for therapies for cancers. . Vascular Endothelial Growth Factor, 
VEGF, is considered the most potent growth factor for angiogenesis (19), is expressed in 
NSCLC, and its levels are correlated with increased tumor microvasculature and poor 
prognosis (20).  VEGF is responsible for initiating signaling cascades that enhance 
endothelial cell proliferation, migration and invasion, mobilization of endothelial 
progenitor cells, and increase the permeability of the existing vasculature (21). Through 
VEGF activation of the phosphoinositide 3-kinase (PI3K) and AKT signaling pathway, 
endothelial cell survival, permeability, and migration is achieved.  These changes 
coincide with Phospholipase C (PLCγ) signaling and result in endothelial cell 
proliferation (18). It is generally accepted that inhibiting a tumor’s blood supply would 
block tumor growth, making components of the VEGF signaling pathway an attractive 
area of research for NSCLC.  Extensive work that has been done in this field leading to 
the development of anti-angiogenic agents including monoclonal antibodies against 
secreted VEGF and tyrosine kinase inhibitors of the VEGF receptor.  
The use of monoclonal antibodies against the secreted growth factor, or small 
molecules to inhibit the kinase domain of the VEGF receptor, is an extremely popular 
therapeutic option (22).  Avastatin (Bevacizumab) was approved by the FDA in 2004 for 
the treatment of NSCLC.  It is a recombinant, humanized, monoclonal antibody that 
binds with all free VEGF-A isoforms, inhibiting the ability of VEGF-A to bind to its 
7 
 
receptor, VEGFR 1 and 2. Bevacizumab was the first anti-angiogenic drug to show a 
favorable outcome with prolonged time to diseases progression (10.6 months vs. 6.2 
months) and increased overall survival (20.3 months vs. 15.6 months) (23).  
Unfortunately, there were several common adverse side affects to bevacizumab 
including; arterial hypertension (one-third of patients), gastro-intestinal perforations, 
wound healing impairment, proteinuria, hemoptysis, arterial and venous 
thromboembolisms, and congestive heart failure (22).  Several small-molecule anti-
angiogenic tyrosine kinase inhibitors were developed; Sorafenib, Sunitinib, Pasopanib 
and Vandetanib, all inhibiting activation of the VEGF receptors 1-3.  However, overall 
these drugs showed only modest increases in progress free survival and no increase in 
overall survival (24-26).   
While classification of histological subtypes of lung cancer and molecular testing 
for pathological differences in subtypes advanced therapy protocols and facilitated the 
development of targeted therapies, there is still need for improvement.   Targeting the 
kinase domains of EGFR and VEGFR were great advances from non-specific general 
radiation and chemotherapy combinations, and addressed both the growing tumor and its 
blood supply.  However, the overall effectiveness of the treatments was modest at best, 
and the numerous side effects speak to the need for continued specificity in novel therapy 
development.  Understanding the complexity of blood vessel formation in the lung in 





1.5 Methods of Tumor Vascularization  
 
The development of a growing tumor requires oxygen, nutrition (glucose), and 
growth factors.  Initially, tumor cells are maintained by passive diffusion, however 
growth in tumor volume beyond 2-3mm3 requires the establishment of a vasculature to 
meet the metabolic needs of the tumor (21).  Without access to a capillary bed, a tumor 
will remain dormant but viable as shown originally by Folkman’s observations of 
xenografts implanted in non-vascular regions of the eye. In these cases, tumors did not 
exceed 2-3mm3, but when removed and implanted in the muscle of rabbits, tumors 
underwent rapid neovascularization followed by rapid growth suggesting the essential 
need for angiogenesis in tumor growth (27, 28).   
There are several methods in which a growing lung tumor can access a blood 
supply: endothelial sprouting, intussusceptive microvascular growth, vessel co-option, 
and vasculogenic mimicry.  Endothelial sprouting is a process in which proteolytic 
degradation to the extracellular matrix of the parent vessel occurs.  This is followed by 
chemotactic migration and proliferation of endothelial cells resulting in the formation of a 
lumen and mature endothelium, generation of new basement membrane and recruitment 
of pericytes (29). Intussusceptive microvascular growth, was first described by Patan et 
al. in 1995 as a state in which the capillary network expands by new formation of small 
intervascular tissue inside existing blood vessels that divides the lumen into two segments 
during tumor vascular remodeling (30).  Vessel co-option, the use of pre-existing vessels, 
was first observed in one of the most densely vascularized organs, the brain. In these 
cases, tumors may develop without the need for angiogenesis, and therefore would not be 
affected by angiogenesis inhibition (31).  In 1999 Maniotis et al. first described 
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vasculogenic mimicry as patterned vascular channels lined by human melanoma cells in 
primary metastatic tumors which subsequently generated a functional endothelial 
network in vitro (32).  With several methods for a growing tumor to access a blood 
supply, and each method relying heavily on the type of tumor, location, and tumor 
microenvironment, it is reasonable to suggest tumor vascularization is highly 
heterogeneous.  Therefore, research focusing on specific methods of vascularization in 
NSCLC is essential.   
Folkman proposed the hypothesis that tumor growth was angiogenesis dependent. 
However, lung tumors uniquely challenge this assumption because of their oxygen rich 
and extremely well vascularized environment.  With the discovery of alternative vascular 
acquisition methods of growing tumors, a more refined assumption in NSCLC is that 
angiogenesis may be involved, but is most likely not the only way a lung tumor is 
vascularized.  Further examining the truly unique tumor growth environment of the lung 
could help us to better understand methods by which lung tumors acquire a blood supply 
and what dictates each method.   
 
1.6 Methods of Tumor Vascularization specific to Non-Small Cell Lung Cancer 
 
A tumor will acquire a blood supply, whether by co-option of neighboring 
vessels, or endothelial sprouting from existing vessels, that often leads to the 
development of a new vasculature that is structurally unsound.  Angiogenic vessels are 
abnormal and highly permeable due to excessive angiogenic growth factor secretion (33), 
resulting in an inefficient vasculature and tumor hypoxia. The response to an hypoxic 
state is the activation of Hypoxia Inducible Factor (HIF) protein signaling, leading to the 
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secretion of VEGF, Platelet Derived Growth Factor (PDGF) and Transforming Growth 
Factor (TGF-α), all of which trigger angiogenesis and tumor microvessel formation from 
the surrounding vasculature (34). Studies of NSCLC have utilized microvessel density 
counting and endothelial staining as a determination of angiogenesis in hundreds of 
patients with NSCLC. Increased microvessel density in histological tumor cross sections 
was shown to predict a poor outcome and shorter survival (35, 36).   
  In a well-vascularized organ, angiogenesis does not always occur to support a 
growing tumor.  Wesseling et al reported non-angiogenic growth of glioblastoma 
multiforme (37), and Hyjeck et al described indolent lymphomas with little formation of 
immature vessels, suggesting a non-angiogenic phenotype (38).  In the lung, Pezzella et 
al characterized non-angiogenic carcinomas by lack of destruction to the parenchyma and 
absence of new vessels, coinciding with an alveolar filling pattern with the only vessels 
present throughout the tumor belonging to alveolar septa (39).  Later this group was able 
to distinguish angiogenic and non-angiogenic tumors by the presence or absence of 
integrin alpha V and integrin beta 3(αVβ3), in blood vessels to describe mature and 
immature vasculature (40).  Highly angiogenic renal cell carcinomas have been reported 
to have numerous non-angiogenic metastases in the lung.  This may imply that the lung 
provides a unique environment for tumor growth without need the need for additional 
neovascularization (41).  Further confirming this theory, Yuneva et al showed that tumors 
of the same lineage develop different metabolic needs depending on the host tissue (42).   
 There is plenty of evidence to support the idea of both angiogenic and non-
angiogenic tumors arising from the same cell lineage (41).  There is also evidence to 
suggest that the tumor host environment could dictate whether a tumor is angiogenic or 
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not (42).  Hence, the poor track record of current anti-angiogenic therapies on non-
angiogenic tumors may not be surprising.  Overall a deeper understanding of the lung as a 
host environment is essential for the development of novel therapy options for NSCLC.   
1.7 The Lung is A Unique Environment for Tumor Growth 
 
The lung provides a unique growth environment for tumors because of its oxygen-
rich environment, unique extracellular matrix and most importantly, its dual circulations 
(43). The dual circulations consist of the pulmonary circulation and the bronchial 
circulation. Each circulation differs in structure, function, and potential for angiogenesis, 
suggesting their roles in tumor perfusion could be drastically different as well.  
Understanding how each circulation would adapt to support tumor growth is essential for 
understanding the unique host environment of the lung. 
1.8 Pulmonary Vasculature Remodeling and Angiogenesis 
 
The pulmonary circulation, a high flow low-pressure circuit, is responsible for 
efficient gas exchange. It tightly regulates fluid movement and prevents fluid leakage 
from the pulmonary vessels into the interstitial space.  This low-pressure system is 
extremely sensitive to any mechanical and chemical changes in the lung that threatens to 
disrupt endothelial function such as acute or chronic hypoxia and increased pulmonary 
flow or resistance.   These types of disruptive changes are often seen in pulmonary 
arterial hypertension, the progressive sustained increase in pulmonary load or vascular 
resistance, where vasoconstriction and remodeling of the pulmonary vasculature leads to 
endothelial cell barrier dysfunction, further exacerbating the increase in pulmonary 
pressure (44).   
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Pulmonary vascular remodeling can be characterized by pulmonary vascular cell 
proliferation, structural wall changes in larger pulmonary arteries, concentric medial 
thickening in small arterioles and muscularization of previously non-muscular capillaries, 
(45, 46).  Drivers of pulmonary hypertension are comprised of several mechanical and 
chemical mediators. Increased vascular pressure, sheer stress and hypoxia result in 
increased pulmonary vascular resistance and reduced vessel compliance (47).  
Angiotensin II was shown to cause hypertrophy and proliferation of pulmonary arterial 
cells (48), while 5-hydroxytraptimine drives vascular remodeling through its 
vasoconstrictor/vasodilator properties and role in vascular smooth muscle cell 
hyperplasia (49). Inflammation and inflammatory cytokines have also been reported to 
play a role in pulmonary vascular remodeling (50).  While pulmonary vascular 
remodeling has been described extensively, angiogenesis from the pulmonary vasculature 
has not been conclusively reported.   
There have been few reports of pulmonary angiogenesis.  In a model of 
pulmonary arterial hypoplasia in fetal lambs, Lambert et al showed transbronchial gene 
transfer of VEGF through an adenoviral vector resulted in pulmonary angiogenesis, 
proximal pulmonary artery growth, and lung parenchyma recovery (51).  Pulmonary 
angiogenesis has also been reported in cases of hepatopulmonary syndrome; a disease in 
which patients with liver disease, due to excessive release of vasodilators, will experience 
vasodilation in the lungs and hypoxemia.  In 2009 Zhang et al. showed in a chronic bile 
duct ligation model of hepatopulmonary syndrome, increased microvessels, PCNA, VE-
cadherin, and Von Willibrand Factor (52). In 2012, they showed VEGF secreting 
monocytes adhere in the lung vasculature leading to increased angiogenesis (53).  In 
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studies of pulmonary hypertension, angiogenesis was quantified by endothelial cell 
staining of CD34 or CD31, which was inconclusive of the process of vascular remodeling 
or true angiogenesis was occurring (54, 55).  McLoughlin and colleagues showed 
increased pulmonary vessel length, volume, and increased endothelial cell count in a 
model of chronic hypoxia in Sprague Dawley rats.  This model also did not show clear 
evidence that either angiogenesis or arteriogenesis was occurring (56).  Beyond fetal 
development, post-pneumonectomy (57), and lung transplant, it is uncertain whether true 
pulmonary angiogenesis occurs.  
1.9 The Bronchial Artery and Angiogenesis  
 
The bronchial artery originates from the superior portion of the thoracic aorta, but 
in some cases can be found originating from the subclavian artery, descending aorta, or 
the brachiocephalic trunk (58).  Typically, two left bronchial arteries and one right 
bronchial artery can be found on the dorsal surface of the main stem bronchi adjacent to 
the ventral surface of the esophagus.  Each artery is approximately 1.5mm in diameter, 
decreasing to 0.5mm when entering the bronchopulmonary segment. The small diameter 
creates a high resistance, low capacitance vessel receiving only about 1% of the cardiac 
output.  The bronchial artery is responsible for perfusing the esophagus, bronchial walls 
down to the level of the respiratory bronchioles, bronchovascular bundles, regional 
lymph nodes, visceral pleura, and eventually drains into the pulmonary arteries and veins 
(59-61). 
Although it is unclear to what extent pulmonary angiogenesis occurs, bronchial 
artery angiogenesis has been described extensively in many different states of lung 
disease. In 1963 Turner-Warwick observed an extensive bronchial vascular network with 
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bronchial-pulmonary anastomoses, and an unchanged pulmonary vasculature in 12 of 16 
lungs with diffuse pulmonary fibrosis (62).  In two different models of pulmonary artery 
obstruction, and functional measurements of blood flow in the bronchial circulation in 
both the lamb and the rat, significant bronchial artery angiogenesis occurs after 
pulmonary artery obstruction (63, 64). In a study of patients with asthma and COPD, 
Calabrese et al described the presence of bronchial artery angiogenesis in histological 
samples (44). Further animal studies of asthma confirmed the appearance of increased 
blood vessels in the airway walls accompanied by increased responsiveness to 
methacholine (65).  While bronchial artery angiogenesis has been observed in several 
lung diseases states, the role of the bronchial artery in tumor perfusion remains 
controversial.    
Whether tumors in the lung are angiogenic, non-angiogenic, or a combination of 
both, it also remains to be determined which circulation is proliferating under angiogenic 
conditions. Several studies utilizing contrast enhanced computed tomography (CT) 
scanning have implicated major roles of both the pulmonary and bronchial circulations in 
tumor perfusion. Since these studies were performed in patients, perfusion data was 
limited to a single time point, without subsequent experiments examining how each 
vascular bed changed with tumor size (66, 67). Further examining the angiogenic 
potential of the pulmonary and bronchial circulation independently could provide 
valuable information for novel NSCLC therapies and increased drug specificity by 




1.10 Aim of the current study 
 
By understanding the physiology and intricate balance of the two circulations 
responsible for lung perfusion, it is possible to better understand how a growing lung 
tumor manipulates these circulations.  Lung tumors can be heterogeneous in their 
methods of recruiting a vasculature, whether they are simply co-opting the existing 
pulmonary circulation, initiating neovascularization of the bronchial circulation, or a 
combination of both.  In this study, we developed an orthotopic model of lung cancer in 
nude rats to examine the pulmonary and bronchial circulations in response to a growing 
tumor.  We assessed tumor growth over time and each circulation’s contribution to 
perfusion depending on tumor size.  We ablated the bronchial circulation after tumor 
establishment and tracked tumor volumes weekly to determine the role of bronchial 
artery perfusion in tumor growth.  We also closely examined endothelial cells from the 
pulmonary artery, pulmonary microvasculature, and bronchial artery to quantify the 
angiogenic potential of both the pulmonary and bronchial circulations.  We hypothesize 
that a lung tumor will grow utilizing the pulmonary circulation until it reaches a critical 
size at which time this circulation can no longer support tumor growth.  We predicted at 
this point the bronchial circulation undergoes angiogenesis and continues to proliferate 











 The dual circulations of the lung are not well described in context with lung tumor 
development.  In part, this is due to the lack of physiologically relevant animal models in 
which to study the disease and the limited capacity for which bronchial perfusion can be 
studied in patients (67).  Essential to examining both the pulmonary and bronchial 
circulatory contributions to tumor perfusion is the development of an animal model that 
allows longitudinal tracking of changes in tumor volumes and perfusion.   
 In the 1960’s-1970 the first in vivo models of lung cancer were developed through 
the induction of pulmonary tumors by exposure to chemical carcinogens (68).  Oral 
administration of dibenz (a, h) anthracene, isonicotinic acid hydrazide, urethane, 
nitrosamines, and chronic inhalation of bis (chloromethyl) ether, as well as two 
components of tobacco smoke; benzo (a) pyrene (B [a] P) and 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK, a nitrosamine), lead to the development of lung adenomas 
(69-75).  These benign nodules were the first attempt at modeling carcinomas, and while 
they were novel and instrumental for proof of concept, the emphasis of each study was to 
block chemical-specific tumor induction. In further development of in vivo models, lung 
adenocarcinomas were induced by carcinogen inhalation paired with oncogene mutations 
in transgenic mice.  Several lines of transgenic mice with P53, KRAS, ARF (ADP 
ribosylation factor 1), ALK and several other oncogene mutations were frequently used, 
with almost 100% of transgenic strains containing a KRAS mutation (76-78).  
Spontaneous formation of lung adenocarcinomas would typically arise without 
carcinogen exposure, however the latency period was long, incidence of nodule 
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formation was low and they were usually accompanied by other malignancies, making 
conclusive mechanistic studies more difficult (79).  These original models of lung cancer 
were sufficient for studying specific carcinogenic mechanisms of lung adenocarcinoma 
development through precise oncogene mutations.  Prevalence and size of nodule 
formation was an easy way to assess the efficacy of drug treatments aimed to block 
tumorigenesis.  Since nodules were small and frequent, studying tumor perfusion was not 
feasible nor the priority of these studies.  
 While several current studies use p53/KRAS mutant mice to drive 
adenocarcinoma formation (80-82) the resulting small diffuse nodules throughout the 
lung are imperfect for studying angiogenesis. A single large tumor would be a better 
option.  Efficacy of angiogenesis inhibiting drugs has been studied in large consolidated 
xenografts that are injected subcutaneously into the flank of nude mice (83-86).  The use 
of nude mice is standard in xenograft models because their absence of T-cells makes it 
unlikely the animal will reject the xenograft.  The ease of physically measuring the 
change in tumor size directly beneath the skin is appealing for large pre-clinical studies. 
However methods by which angiogenesis inhibiting drugs block angiogenesis in the flank 
seem unlikely to be translated to the lung. This is because the microenvironment of a 
tumor growing subcutaneously in the flank is hypoxic and nearly avascular, contrasting 
from the oxygen rich and extremely well vascularized environment of the lung.  
Additionally, inadequacies of the subcutaneous flank model are evident by the lack of 
effective anti-angiogenic therapies for NSCLC to date (87-90).  
 Given the shortcomings of the subcutaneous flank model of NSCLC, and that the 
more physiologically relevant transgenic mouse models result in small diffuse nodules, 
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additional xenograft models were developed to address this issue.  Several orthotopic 
studies modeling adenocarcinomas utilized A549, H1975, HCC4006 and HCC827 cells 
derived from patients (91-93), and were injected along with a matrigel vehicle into the 
lung of nude mice (91, 94, 95).  The resulting lung tumor was ideal for studying 
extracellular matrix, tumor microenvironment, and novel chemotherapy approaches.  
With orthotopic mouse models being the most ideal, physiologically relevant model thus 
far, only the issue of the lung’s dual circulations remained.  
 To truly be able to study the dual circulations of the lung and their ability to 
support tumor growth, it was essential to select a small animal that has an established 
bronchial circulation. The mouse lacks a sub-carinal bronchial circulation (96, 97).  
Studying lung tumor angiogenesis in the mouse would not be an accurate portrayal of 
angiogenesis in patients with NSCLC because the growing lung tumor would rely 
entirely on the pulmonary circulation for perfusion, which has been shown to have 
diminished angiogenic capacity (98). The rat not only has an established bronchial 
circulation, but one that has been studied in other lung disease states including asthma 
(65), pulmonary fibrosis (99), and chronic pulmonary thromboembolism (63, 64). Thus, 
the rat provides a more physiologically relevant way to study the bronchial circulation 
than the mouse.  
 Additionally, the need for a single, rapidly growing tumor in the lung, made an 
orthotopic xenograft model the best option. We chose to use RNU nude rats for the 
xenograft because of their established bronchial circulation and anatomical relevance to 
humans, with the experimental convenience and ease of having a small animal model.  In 
this study we developed an orthotopic model of NSCLC that is pathologically and 
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physiologically similar to patients with NSCLC that allowed us to study both the 

















Adenocarcinoma Cell Injection: The experimental protocol was approved by the Johns 
Hopkins Animal Care and Use Committee (Protocol #RA12M283). Human lung 
adenocarcinoma cells (Calu-3, ATCC, Manassas, VA) were grown in culture, 
DMEM+10% FBS, until confluent in T75 flasks. Cells were trypsinized, and 5million 
cells were resuspended in 50μl of sterile saline.  Rats were anesthetized with isoflurane 
(2% with room air), intubated, placed on a rodent ventilator model 683, Harvard 
Apparatus, Holliston, Massachusetts (90 breaths/min; 8ml/kg tidal volume).  A transverse 
incision (1.5inches) was made with a scalpel into the skin covering the thorax on the left 
side. The tissue was dissected until the rib cage was exposed. With a 31G Insulin Syringe 
(BD Biosciences, San Jose, CA), cells were injected through the thorax (between the 3rd 
and 4th rib) directly into the left lung.  The incision was closed with methyl acrylamide 
adhesive and the rats were allowed to recover (5-10minutes) while being ventilated with 
room air before being extubated and returned to their cages.   Animals were maintained in 
the lab and observed daily for weight loss and signs of distress for 2-12 weeks after 











Lung fixation for histological visualization of lung adenocarcinoma: Animals were 
sacrificed by lethal dose of pentobarbital sodium salt solution (Sigma, St Louis, MO; 
50mg/ml) at a time course from 1-10 weeks after cancer cell injection. The trachea was 
exposed and a 14G, 1.5” blunt needle (SAI Infusion Technologies, Lake Villa, IL) was 
secured in the trachea.  Z-FIX (Anatech LTD, Battle Creek, MI) was infused into the lung 
through the tracheal cannula and held at 10cmH2O for 24hours. Lungs and heart were 
dissected en bloc from rat and placed in Z-FIX for an additional 48 hours and 70% 
ethanol for a minimum of 24hours. Samples were embedded in paraffin blocks and slides 
were made from 10μm thick tissue slices from the left lung cut transversely through the 
center of the lung tumor, which was visible by inspection.  Haematoxylin &Eosin 
staining was performed on slides and pictures were taken at 40X original magnification 
using SPOT imaging software 5.1 (Diagnostic Instruments Inc, Sterling Heights, MI).  
 
Immunohistochemistry for visualization of tumor vasculature: Slides were de-
paraffinized by rinsing with 100% xylenes (Electron Microscopy Sciences, Hatfield PA), 
100%, 95%, 70% and 50% ETOH. Antigen retrieval was performed by boiling 1mM 
EDTA (Thermo Fisher Scientific,) then adding to slides and microwaving on lowest 
power for 10minutes. Slides were then cooled with room temperature water. Blocking 
was performed with 10%FBS, 1%BSA, and 0.5%Tween20 in PBS for 60 minutes. 
Antibodies for Tomato Lectin (Endothelial cell marker; Sigma) and ERBb2 (Epithelial 
cell marker over expressed in lung adenocarcinomas; Thermo Scientific) were incubated 
at room temperature for 2 hours. Slides were dehydrated through ethanol series (50%, 
70%, 80%, and 95%) and 100% xylenes for 1minute. 20ul of Prolong Gold anti-fade 
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reagent with DAPI (Nuclear stain; Life technologies) was added to each slide sealed with 
a coverslip. Images were taken at 100X original magnification using an Olympus IX51 
microscope (Olympus, Center Valley, PA) and High Performance SensiCam (Cooke, 
Auburn Hills, MI).  
 
Tumor volume determination by High Resolution Computed Tomography (HRCT) 
scans: 
Rats were anesthetized with a ketamine/xylazine (75/25 mg/kg) solution. HRCT scans 
were performed in the Department of Radiology, CT at the Johns Hopkins Outpatient 
Center on a Siemens Definition Flash 256 slice dual source scanner. Scanner settings are 
listed below.  
Representative images of a lung tumor six weeks after adenocarcinoma cell 
injection in one rat are depicted in Methods Figure 2.  Scrolling through the stack of 
images, the apex and the base of the tumor were identified.  Using Image J, a region of 
interest (ROI; yellow outline) was drawn around the border of the tumor in each image 
where the tumor was identified.  Image J software was calibrated based on pixel size 
(0.10 x 0.10 mm).  The sum of the areas from the ROI for each image was multiplied by 
the slice thickness (0.4 mm) and then summed over all the ROIs to calculate tumor 
volume.  (Note: only five representative images are shown from approximately 50 total 






Methods Fig 1: Tumor Volume Calculation 
 
 
Table 1: Sample calculation of tumor volume by HRCT scanning 





Σ (1-4) =133.43 
Σ (1-4) X Slice Thickness =(133.43) X 0.4= 53.37mm3 





HRCT scanner settings: 
 Collimator: Ultra High Resolution (16 x 0.3mm) 
 Kernel: V80µ Very Sharp 
 Effective mAs: 450 
 Pitch value: 0.85 
 kV: 120 
 Direction: Craniocaudal 
 Slice: 0.4 x 0.2 mm 
 Rotation time: 1 second 
 Lung window: Width-1600 Level-500 
 Field of View: 50 mm 
 Reconstructions: Iterative 
 
Table 1: Sample calculation of tumor volume by HRCT scanning 
Regions of interest were drawn around the tumor, on every image that a tumor was visible, in all 
of the images making up the thorax. All areas of regions of interest were summed and multiplied 




Left Pulmonary Artery Ligation:  
Because the pulmonary circulation was presumed to be involved in tumor perfusion, in a 
separate series of rats the left pulmonary artery was ligated prior to adenocarcinoma cell 
injection to determine if the bronchial circulation was sufficient to support tumor 
establishment and growth.   
 
The experimental protocol was approved by the Johns Hopkins Animal Care and Use 
Committee (RA13M461). Seven-week-old RNU nude rats (Charles River, Boston 
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Massachusetts) were anesthetized (2% Isoflurane in room air) intubated with 14G 
intracath and ventilated (90 breaths/min; 8ml/kg tidal volume) (Rodent ventilator Model 
683, Harvard Apparatus, Holliston, Massachusetts). With rats lying on their right side, a 
transverse incision was made into skin directly over the left side of the thorax and tissue 
was dissected until ribs were exposed. A blunt incision was made between the 3rd and 4th 
rib on the left side of the thorax, and rib separators were inserted into the space creating 
an opening to visualize the left lung.  The Left pulmonary artery was isolated from the 
left bronchus and ligated using 6-0 polypropylene suture (Myco Medical, Cary NC). The 
lung was hyper-inflated to reestablish thoracic pressure as thorax was closed with 4-0 
suture (Myco Medical, Cary NC).  Sensorcaine (Bupivaciane 2mg/kg) was injected at the 
site of the incision for analgesia and the incision was closed with methyl acrylamide 
adhesive.  The rats were allowed to recover on ventilator breathing room air (5-
10minutes), then were extubated and returned to their cages (69).  
 
Statistics: 
Linear regression and goodness of fit in Prism Graph Pad software was used to calculate 







Fig 1:Adenocarcinoma cell injection results in single tumor development 
After the injection of 5 million adenocarcinoma cells, a single, solid tumor develops in the left 







Histological confirmation of lung adenocarcinomas 
 After adenocarcinoma cell injection, histology was used to monitor tumor growth 
and confirm the growing tumors displayed the same pathology that would typically be 
found in a patient with NSCLC.  Examination of tumor cross sections from 7 different 
animals over a time course from 2-8 weeks after adenocarcinoma cell injection showed 
the formation of one consolidated tumor. A progressive increase in tumor diameter over 
time was observed (Fig 2A).  Upon further examination through serial sections of the 
right and left lung, only one tumor was detected indicating there were no metastatic 
lesions to the rest of the lungs.  H&E staining depicted well-differentiated epithelial cell 
patterns, surrounding and filling airways and alveolar structures.  Tumor histological 
patterns were heterogeneous in nature, illustrating lepidic (alveolar lining), acinar (gland 
forming), and papillary (fibrovascular core) patterns indicative of lung adenocarcinomas. 
Each tumor had defined borders that both appeared to fill existing alveolar structure in 
some areas, while pushing out and condensing the surrounding alveoli in others (Fig2B).  
Lung tissue surrounding the tumor appeared to be normal and healthy based on 
maintained alveolar structure, lack of inflammatory cell infiltrate and no apparent 
vascular edema. Unfortunately from H&E staining, only the presence of red cells, and the 




Fig 2: Histological confirmation of tumor formation over eight weeks 
Fig.2 A, C, E, F: H&E Staining of histological sections confirms presence of a single tumor, with 
a progressive increase in tumor diameter over time.  No metastatic lesions were observed in the 
lung.  The presence of red blood cells and absence of necrotic regions suggest a well-vascularized 
tumor. (40X original magnification) 
B, D) Condensed alveoli surrounding tumor borders suggest tumor growth is achieved by pushing 
through nearby tissue (black arrows), while maintained alveolar structures suggest alveolar filling 









      

















To better visualize the tumor vasculature, immunohistochemistry was used to 
distinguish the tumor vasculature from adenocarcinoma cells.  Tomato lectin (red) was 
used to label endothelial cells, ERBb2 (green) was used to label adenocarcinoma cells, 
and DAPI (blue) was used as a nuclear stain.  By utilizing fluorescently labeled 
antibodies, and multi-channel fluorescent microscopy, it was possible to visualize 
vascular patterns, and tumor growth patterns of adenocarcinoma (Fig 3).  In patients, lung 
adenocarcinomas have been defined by well-differentiated tumors that display alveolar 
filling patterns with little destruction to lung parenchyma.  Pathological reports have 
described the presence of a vasculature belonging to the existing alveolar septum with 
tumors growing around these structures.  Distinct alveolar filling patterns were observed 
in the orthotopic xenograft after adenocarcinoma cell injection.  The incidences of blood 
vessels also appear to be from the existing microvasculature (Fig 3A,B). Acinar and 
papillary patterns were confirmed in xenograft sections (Fig 3C).  After histological 
examination of the orthotopic xenograft it appeared that the tumor pathology was similar 





Fig 3: Immunohistochemistry used to confirm adenocarcinoma pathology 
Immunohistochemistry was used to confirm lung adenocarcinoma pathology (6 weeks after 
adenocarcinoma cell injection; images are 100X original magnification). Tomato Lectin (red) was 
used as endothelial cell marker, ERBb2 (green) was used as adenocarcinoma cell marker, and 
DAPI (blue) was used as a nuclear stain.  A-B) Tumors display typical adenocarcinoma pattern; 
growing along alveolar septa, displaying alveolar filling, minimal structural damage to 
parenchyma (red arrows). C) Pathological heterogeneity is displayed in separate region of tumor. 
Acinar structures, with gland formation arranged around a central lumen (red arrow), are 



















Tracking tumor growth by HRCT scanning 
To quantify tumor growth over time, we utilized HRCT scanning to quantify 
tumor volume weekly in a series of 6 animals (see methods; Fig 1).  A single tumor could 
first be visualized in the left lung between 2 and 3 weeks after adenocarcinoma cell 
injection.  We then observed a progressive increase in tumor volume over the course of 8 
weeks, with no sign of secondary lesions to other regions of the lung (Fig 4A).  When 
tracking tumor volumes it was evident that growth patterns varied greatly in rate of tumor 
growth between animals, with some animals showing drastic increases in tumor volume 
from week to week while others’ showed slower growth patterns while other even 
plateaued.  Exact tumor location and final tumor volumes at the end of 8 weeks were also 




Fig. 4: Tumor Volume Quantification by HRCT scanning  
 
A) Thoracic HRCT images from a single rat at four time points after injection of adenocarcinoma 
cells.  At week 3, a single solid adenocarcinoma can be seen in the left lung  (Tumor is outlined in 
yellow).  The HRCT scans at weeks 4 and 8 demonstrate the progressive increase in tumor size 
over time. Tumor volume was calculated from the summation of the serial regions of interest 
(yellow outline) on the image slices containing the tumor (see calculations in methods). B) 
Demonstrates the progressive increase in tumor volume (cm3) in each rat as determined by HRCT 
scans over the course of eight weeks. Each line represents a single tumor in different individual 





















In a separate series of 7 animals, tumor volumes were quantified by HRCT 
scanning then dissected and their weight was measured.  Tumor volume was significantly 
correlated with tumor weight (r2=0.98, p<0.0001) demonstrating the accuracy and 
consistency of the HRCT scanning measurement to quantify tumor size.  This correlation 
also demonstrates the consistency in density of tumor composition between animals (Fig 




Fig 5: Confirmation of HRCT volume measurements 
In a separate series of rats (n=7), tumor volume as measured by HRCT was significantly 
correlated with tumor weight by pathology (r2=0.98, p<0.0001). These results demonstrate the 
accuracy of the HRCT scanning method to measure tumor size.  Correlation also indicates 












Determining the importance of the pulmonary circulation for lung tumor 
establishment 
Because the pulmonary circulation is presumed to be essential for tumor 
establishment, especially in the case of pulmonary metastases, we examined whether the 
bronchial circulation alone would be adequate for tumor establishment and growth.  The 
left pulmonary artery was ligated immediately prior to adenocarcinoma cell injection 
(n=5).  Animals were sacrificed and tumor weight was measured 4 weeks after 
adenocarcinoma cell injection.  Tumor weights were significantly decreased in animals 
receiving the pulmonary artery ligation than animals with an intact pulmonary artery 
(*p=0.018) indicating the importance of the pulmonary circulation for tumor 





Fig 6: Tumor weight after pulmonary artery obstruction 
 The pulmonary artery was ligated prior to adenocarcinoma cell injection. Tumor volume was 







2.4 Discussion:  
 
Models of NSCLC have evolved for decades to keep up with the discovery of new 
therapeutic targets or mechanism being examined, however the lack of a physiologically 
relevant lung cancer models has limited mechanistic studies of the vascular sources.  
Common xenograft models in rodents using the flank lack the circulatory complexity of 
the lung, and mouse lung models are inadequate due to the fact that mice lack a sub-
carinal bronchial vasculature (100).  In this study we developed a model that would allow 
us to quantify changes to the two vascular beds in response to tumor growth. 
With the development of this model came measures to confirm that the 
adenocarcinoma cell injection would result in the formation of a single tumor.  
Xenografts typically use matrigel vehicles with cancer cell injections to maximize the 
incidence of tumor formation.  We chose to use sterile saline as a vehicle in attempts to 
create the most native microenvironment for tumor growth.  While the exact location of 
the injection would change slightly between animals, all developed tumors in the lung 
periphery.  Because we were successful with saline, there was no need to include the 
additional extracellular matrix components with the injection.   
In effort to make more refined quantifications of tumor growth than simply 
measuring tumor diameter in histological sections, we quantified tumor volume by HRCT 
scan and then measured the weight of each tumor.  Not only did the correlation between 
weight and volume confirm the reproducibility of HRCT volume calculations, it gave us 
additional insight to the consistency of tumor density between animals.  Because of the 
significant correlation between tumor volume and tumor weight, we concluded that the 
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density of the tumor remained constant between animals as it increased in volume (Fig 
4).   
By HRCT imaging and histological examination we confirmed that after 
adenocarcinoma cell injection a small, consistently solid tumors would begin to grow 
varying slightly in the location of origin depending on injection location. There were no 
observed necrotic regions in the tumors, or irregular growth patterns depicting a 
pathologically different subtype of NSCLC when assessed by histology.  A progressive 
increase in tumor volume, as assessed by HRCT scans, and tumor diameter, as assessed 
by H&E staining, were observed over the course of eight weeks (Fig 2 and 4A). Growth 
rates varied between animals with differences in final tumor volumes at 8 weeks, with 
apparent peaks and plateaus in tumor growth from week to week. While the magnitude of 
growth differs, interestingly all animals seemed to have a plateau in tumor growth 
between 5 and 7 weeks, followed by an increase in tumor growth between 7 and 8 weeks 
(Fig 4B).  Perhaps these growth patterns could be indicative of neovascularization 
facilitating further tumor growth.  
Morales-Oyarvide and Mino-Kenudson extensively define the pathology of lung 
adenocarcinomas. They described tumor islands, a method by which lung tumors invade 
through and fill airways that is unique to the lung, as an atypical means of invasion 
characterized by the absence of parenchymal destruction (101).  In observation of tumor 
pathology, airway filling and the presence of tumor islands was present in histological 
sections (Fig2; 4 week image, two airways depict tumor islands).  Pezzella and 
colleagues discussed the alveolar filling pattern where tumors grow efficiently by 
exploiting the existing vascular network rather than destroying alveolar spaces (102).  In 
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histological sections alveolar filling patterns were extremely common, occurring in every 
section analyzed (Fig 3 A, B) as well as gland forming, acinar patterns, with 
micropapillay structures that are hallmarks of adenocarcinomas (Fig 3C). It was evident 
that the adenocarcinoma cells grown in culture maintained their pathological phenotype 
of after injection into the lung as assessed by histology.  
Since the pulmonary artery has been shown to play a large part in lung tumor 
perfusion (134) we questioned the importance of the pulmonary circulation for tumor 
growth. Tumor weight was significantly decreased in animals receiving the pulmonary 
artery ligation compared to those with an intact pulmonary artery, with two animals that 
failed to establish a tumor at all.  These data indicate the pulmonary circulation is 
necessary for tumor establishment and growth.  While there was a small amount of 
oxygen in the venous blood in the pulmonary circulation (PO2=40mm Hg), and since the 
lung was ventilated creating an oxygen rich environment, perhaps the nutrients and small 
amount of oxygen in the venous blood from the pulmonary artery were necessary to aid 
in initial tumor establishment and growth, before the bronchial circulation was large 
enough to make a substantial contribution to perfusion.   
This study focused on one cell line, grown in culture and then injected as a 
xenograft into the left lung of nude rats.  Certainly a bolus of adenocarcinoma cells 
injected into the lung would not be as precise mechanistically as transgenic models where 
tumor formation occurs naturally.  However considering time constraints, and the desire 
for a single rapidly growing tumor, a xenograft was the best option.  While IHC staining 
of histological sections was informative and essential for visualization of tumor 
vasculature, tomato lectin antibodies stained all endothelial cells and did not allow us to 
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distinguish specifically between the bronchial and pulmonary circulations.  Because of 
the great heterogeneity of the adenocarcinoma pathological subtype in patients (103), 
perhaps an even more relevant model would be to obtain patient samples of lung 
adenocarcinomas for xenograft injection.  
2.5 Conclusion: 
 
 In efforts to design an ideal model for studying the bronchial versus the 
pulmonary circulatory involvement in lung tumor perfusion, we developed a 
reproducible, physiologically and pathologically relevant orthotopic xenograft model in 
nude rats.  We observed a progressive increase in tumor size over the course of 8 weeks, 











3.0 Quantification of angiogenesis by fluorescent microsphere injection 
3.1 Introduction: 
 
In a 1991 publication Auerbach and colleagues wrote, “Perhaps the most 
consistent limitation to progress in angiogenesis research has been the availability of 
simple, reliable, reproducible, quantitative assays of the angiogenesis response ”(104).   
Indeed this statement still holds truth 25 years later.  One of the biggest challenges in 
studying lung tumor angiogenesis in vivo is finding a simple, reliable, reproducible 
quantitative model. Determining the best method for quantifying new blood vessel 
formation is challenging and only made more difficult in a well-vascularized organ like 
the lung where there is the additional need to distinguish between the original and new 
vasculature as well as between the pulmonary and bronchial circulations.  
Several in vivo models have been used to study angiogenesis.  Perhaps the most 
common in vivo method over the last 15 years is the chick embryo chorioallantoic 
membrane (CAM) assay (105, 106).  This extra-embryonic membrane mediates gas and 
nutrient exchange for a chick embryo during the 21 days of development. 
Neovascularization occurs rapidly, which is ideal for studying angiogenesis and 
angiogenesis inhibiting drugs (107).   Other common models for studying angiogenesis in 
vivo include 3D subcutaneous implantation of matrigel plugs or polymer sponges into the 
back or flank of mice and rats (108, 109), and more recently zebra fish embryos for 
studying angiogenesis in tumor xenografts (110) .  While these methods have had success 
in studying general angiogenesis, the differing angiogenic mechanisms in the CAM 
assay, or in a subcutaneous matrigel plugs decrease their value in studying angiogenesis 
specific to the lung.   
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The most direct methods for studying angiogenesis in the lung, which allow for 
visualization of functional blood vessels, are vascular casting in animal models and 
vascular angiography in patients (111, 112).  Vascular casting involves the injection of a 
liquid into the vasculature of an animal that will polymerize and harden.  The tissues of 
interest can be dissected and digested or made translucent for visualization of the 
vascular cast providing an excellent depiction of neovascularization.  Vascular 
angiography is similar but can be done in patients for blood vessel visualization.  
Typically a contrast medium is injected to highlight the vasculature and images are 
obtained by X-ray or CT scan.  A grading system can be used to quantify the degree of 
neovascularization in patients with different disease states. Both of these methods are 
ideal for visualization of a vascular bed, however quantification is not entirely objective.  
When studying small changes in tumor perfusion from two vascular beds an accurate, 
quantitative measurement is essential. 
Currently the most common way of quantifying angiogenesis in the lung is in an 
ex vivo setting.  It is extremely popular in both animal and patient studies of fibrosis, 
pulmonary hypertension, lung tumors, and ischemia-induced angiogenesis to use 
microvessel density counting (113-119). In this method of angiogenic assessment, 
histological sections are created from lung or tumor cross-sections (in animal models) or 
tumor biopsies from patient samples.  These sections are incubated with endothelial cell 
markers, usually CD31, for identification of endothelial cells.  Once the tumor 
vasculature is outlined by CD31 staining, vessel length, diameter, and endothelial cell 
count are calculated for a given region of interest.  While this method is convenient, and 
useful in patient samples where tissue is limited, it does not provide much valuable 
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information in the context of the lung.  Since the endothelial cells of the native 
pulmonary microvasculature will stain positively for CD31 there is no way to distinguish 
neovascularization from the native vasculature.  Proper lung inflation during fixation for 
histological sectioning is critical.  A section of condensed, underinflated lung would have 
a greater microvessel count/unit area than a lung that was inflated and fixed properly.  
This method also does not provide any information on the functionality of the vessels.   
Additional ex vivo measurements of angiogenesis include quantifying circulating 
growth factors and endothelial cells.  Circulating endothelial cells should be rare, but 
measurable in healthy individuals and have been shown to increase in patients with 
NSCLC (120). This population of cells can be defined by CD105+, CD146+, Cd45- 
markers (121).  However, the correlation between circulating endothelial cells, disease 
prognosis, and progression free survival is still controversial (122-124). Circulating 
VEGF isoforms, VEGF receptors FLT1, and KDR, fibroblast growth factor (FGF), 
platelet derived growth factor (PDGF), and several other biomarkers have been used as 
indicators of angiogenesis in patients with NSCLC (113, 125-127). Vascular analysis by 
RT-PCR expression of these biomarkers has also been done in patient samples as well as 
xenograft models in the mouse (128). While all of these ex vivo models are informative 
and suggestive of an angiogenic response, they do not quantify or visualize 
neovascularization to the lung or the lung tumor.    
 Fluorescent microsphere injection has been used previously for quantification of 
systemic perfusion in vivo in models of pulmonary ischemia (69) as well as lung tumor 
xenograft models in (135).  In this method, a predetermined number of labeled 
microspheres (10-15um) are injected into the systemic circulation where they flow to 
49 
 
peripheral organs and lodge in precapillary beds Use of fluorescent spheres has largely 
replaced the use of radiolabelled microspheres used originally by Rudolph and Heymann 
(129).  Tissues of interest can easily be dissected, digested and fluorescence can be 
quantified as total microspheres lodged in a specific tissue, or as a percentage of cardiac 
output based on the total number of microspheres injected into the circulation.  This 
method provides a reproducible, quantitative measurement of functional perfusion (64). 
In this study we sought to quantify lung tumor angiogenesis by fluorescent microsphere 
injection.  By adapting this method to include two different colored microspheres, and 
two injection sites, we were able to quantify tumor perfusion from both the pulmonary 







Blood Flow Determination by Microsphere Injection:  
By utilizing two injection sites, quantification of fluorescent microspheres was used to 
determine tumor perfusion from both the pulmonary and bronchial circulations. 
Microspheres injected into the aortic arch (via carotid artery catheter) represented the 
systemic perfusion to the lung and lung tumor, and microspheres injected into the 
pulmonary artery (via femoral vein catheter) represented the pulmonary perfusion to the 
lung and lung tumor.  
 
Surgical Procedure: 
Rats were anesthetized (2% isoflurane in room air), intubated and ventilated (90 
breaths/min; 8ml/kg tidal volume) with a rodent ventilator (model 683, Harvard 
Apparatus, Holliston, MA).  A midline incision was made directly over the trachea with a 
scalpel, the tissue was dissected to reveal the trachea, and the left carotid artery was 
isolated. A catheter filled with heparinized saline was placed with a cut down retrograde 
into the carotid artery, and secured (Methods Fig 2A). Another incision was made on the 
medial surface of the left hind limb and tissue was dissected to expose the femoral vein. 
The vein was isolated and a second catheter containing heparinized saline was inserted, 
and secured (Methods Fig 2B).   One million, 10μl yellow polystyrene fluorescent 
microspheres (1 x 106 spheres/ml; Invitrogen, Eugene, OR) were infused into the femoral 
vein catheter using a syringe pump (rate: 500 μl/min; Genie Plus, Kent Scientific, 
Torrington, CT) (Methods Fig 2C). The catheter was flushed with 1ml heparinized saline 
by perfusion pump (500 μl/min). Subsequently, crimson polystyrene fluorescent 
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microspheres (1 x 106 spheres/ml; Invitrogen, Eugene, OR) were infused through the 
carotid artery catheter into the aortic arch and that catheter was flushed with a 1ml 
infusion of heparinized saline. Prior to this systemic microsphere infusion, the left 
pulmonary artery was transiently occluded  (previously described in Chapter 2, methods 
for left pulmonary artery ligation) to prevent potential recirculation of systemic spheres to 
the left lung. After this infusion was complete, the rats were exsanguinated and the lungs 
were extracted. Lung tumors were easily visualized and carefully dissected from lung 
tissue (Methods Fig 2D).  
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Tissue Digestion and Analysis: 
The tumor, left lung, right lung, left kidney, and right kidney (kidneys were used as 
controls to ensure adequate and consistent systemic perfusion at the time of injection), 
were weighed and placed in 2M KOH (4-6ml) solution over night at 55oC.  Tween 80 
(0.25%) was added to wash microspheres and samples were centrifuged (2,000 rpm; 20oC 
for 10 min) according to methods established by manufacturer (Invitrogen, (64)).  
Supernatant was removed and 1ml of 2-ethoxyethyl acetate was added to each sample 
and incubated for 1 hour. Samples were centrifuged again and aqueous layer of 2-
ethoxyethyl acetate containing fluorescence was collected and placed in a cuvette.  
Fluorescence of crimson microspheres (ex-625/em-645) and yellow microspheres (ex-
505/em-515) was measured using a Hitachi F-2500 fluorescence spectrophotometer  
(Digilab, Holliston, MA).  Using the slope of the standard curve (microsphere # vs. 
fluorescence) that was calculated from each bottle of microspheres, we delineated the 














Table 2: Sample Calculations of one rat for Microsphere Number from Fluorescence 
Measured 
CRIMSON      
      
 Fluorescence Fluorescence 







LL#1 30 30 0.31 96.77 2614.33 
RL#1 153 153 0.7 218.57 13333.10 
Tumor #1 65 65 0.37 175.67 5664.39 
LK#1 467 467 0.78 598.71 40696.48 
RK#1 256 256 0.86 297.67 22308.99 
      
      
      
YELLOW      
      








LL#1 6760 6620 0.31 21354.83 25156 
RL#1 100569 100429 0.7 143470 381630.2 
Tumor #1 1207 1067 0.37 2883.78 4054.6 
LK#1 488 348 0.78 446.15 1322.4 
RK#1 260 120 0.86 139.53 456 
      
      
      
Tumor Microspheres     
      
YELLOW CHRIMSON Total %pulmonary %bronchial  






Cryomicrotome Imaging of Fluorescent Microspheres 
 
In collaboration with Dr. Robert Glenny at the University of Washington, cryomicrotome 
imaging was used to visualize fluorescent microspheres from the pulmonary and 
bronchial circulations lodged in the lung and tumor microvasculature (131).  For this 
imaging protocol, 1 million yellow 15 μm microspheres were infused into the systemic 
circulation, and 40,000 red 15μm microspheres were infused into the pulmonary 
circulation by methods previously described (red was used instead of crimson in this case 
for image optimization). Since the purpose of this experiment was to visualize the 
bronchial circulation’s involvement in tumor perfusion, 40,000 microspheres were 
sufficient for visualization of the pulmonary circulation without overwhelming the 
images and impairing the imaging of the bronchial circulation.   After microsphere 
injection 5ml of clear OCT was injected into the trachea to fix the lungs. Heart and lungs 
were removed en bloc, embedded in OCT and sent to Dr. Glenny’s laboratory at the 
University of Washington for lung sectioning and imaging (131).  
Briefly, the Imaging Cryomicrotome (Barlow Scientific, Inc., Olympia, WA, 
USA) sectioned the frozen lung and photographed the tissue auto-fluorescence and FMS 
distribution at high resolution (131). The Imaging Cryomicrotome consists of a Redlake 
MegaPlus II ES 3200 digital camera (San Diego, CA, USA) with a resolution of 2184 × 
1472 pixels, a metal halide lamp (PE300BF Cermax, Excelitas Technologies, Fremont, 
CA, USA), and filters limiting the excitation and emission wavelengths. Fluorescence 
images were acquired with a 180 mm Micro-Nikkon lens (Nikon, Corp., Tokyo, Japan). 
A custom-built LabVIEW (version 8.2, National Instruments Inc., Austin, TX, USA) 
application controls the motor, emission and excitation filter wheels, fine-focus, and 
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image capture and display. The slice thickness was 24μm, and the camera was set at a 
distance from the sample surface to give an isotropic in-plane resolution of 24μm. 
 
 
Statistics:    
Prism Graphpad software was used to perform the statistical analyses. Linear 
regression and goodness of fit was used to calculate the correlation total microsphere 
number (total tumor perfusion) with tumor weight.  A paired T-Test (two-tailed) was use 
to determine significance between perfusion to small and large tumor groups quantified 
by microsphere injection and an un-paired T-Test and Mann Whitney posttest were used 
to determine significance between left lung tissue in small and large tumors.  An unpaired 
T-Test (two-tailed) was used to determine significance between the tumor weights at 5 
weeks after left pulmonary artery ligation. Significance is represented 










Tumor Perfusion by fluorescent microsphere injection 
 In efforts to quantify lung tumor angiogenesis it was essential to utilize a 
functional measurement of tumor perfusion. In naïve rats, less than 0.5% (~5,000 
microspheres) of the cardiac output could be detected by systemic microspheres in the 
left lung. We observed a significant correlation between total tumor perfusion (total 
microsphere number; pulmonary+ bronchial microspheres) and tumor weight (p=0.017; 
Fig 7A).  When pulmonary and bronchial circulations were examined individually, 
similar patterns were observed. Both microspheres from pulmonary circulation (p= 
0.0170) and bronchial circulation (p<0.0001) were significantly correlated with tumor 






Figure 7: Tumor perfusion measured by microsphere injection  
A) The total number of microspheres counted in the tumor (bronchial + pulmonary perfusion) 
was significantly correlated with tumor weight (r2= 0.365; p=0.017).  
B) Total microspheres from both the pulmonary circulation (r2=0.3652, p= 0.0170) and the 











Originally, when quantifying tumor perfusion we examined each circulation’s 
contribution from 4-12 weeks after adenocarcinoma cell injection.  Because of variable 
tumor growth rates between animals, confirmed by HRCT scanning, tumor weight and 
perfusion were variable at any given time point.  Since we observed a correlation 
between total tumor perfusion and tumor weight, all subsequent perfusion measurements 
were correlated with tumor size instead of a pre-selected time point after adenocarcinoma 
cell injection. We divided tumors into two groups by weight; large tumors (>0.5g) and 
small tumors (<0.5g) and quantified total tumor perfusion from each circulation.   The 
percentage of total tumor perfusion from the pulmonary circulation is significantly 
decreased in large tumors, and the percentage of total tumor perfusion from the bronchial 





Figure 8: Tumor perfusion in small and large tumors 
When tumors were partitioned into two groups by weight (small;<0.5g vs. large; >0.5g),  
A) The large tumors had a significant decrease compared to the small tumors in the percentage of 
microspheres from the pulmonary circulation (**p=0.003). B) Coinciding with a significantly 
higher percentage of microspheres from the bronchial circulation in large tumors than small 











Left lung perfusion by microsphere injection 
 
When quantifying tumor perfusion from each circulation it was also of interest to 
quantify perfusion to the remaining tissue from the left lung to determine if angiogenesis 
was isolated to only the tumor or if there were global changes to the entire left lung.  
There was no significant change in pulmonary circulation (p=0.73) or bronchial 
circulation (p=0.12) to the left lung between animals with small or large tumors 





Figure 9: Tumor perfusion from pulmonary and bronchial circulations does not 
increase in left lung tissue. 
Microspheres from the pulmonary and bronchial circulations in the left lung tissue surrounding 
the tumor were quantified.  There was no change to A) the pulmonary circulation in the left lung 
between small and large tumors (p=0.73) or B) the bronchial circulation in the left lung between 










Microsphere Visualization by Cryomicrotome Imaging 
After quantifying lung and tumor perfusion by fluorescent microsphere injection, 
we sought to visualize the fluorescent microspheres and their location in a tumor using 
cryomicrotome imaging. The bronchial circulation was well defined in lung cross-section 
images with clear lodging of microspheres in bronchial vessels (indicated by red arrows) 
in the mainstem bronchi.  Other small systemic vessels, originating from the aorta and 
esophagus, could be visualized by fluorescent microspheres as well. (A and E in Fig 
10C).  Clusters of microspheres can be seen throughout the tumor as well as sporadically 
throughout the lungs depicting the bronchial vessels (Fig 10C).  The pulmonary 
circulation was well defined by red fluorescent microspheres spread diffusely throughout 




Figure 10: Cryomicrotome Imaging for visualization of fluorescent microspheres  
Approximately 2,000 lung sections from base to apex of lung were imaged, each section 24μm 
thick. A) Caudal view of lungs and heart section embedded in black OCT block. B) Section in 
UV light exposure highlights collagen for depiction of heart; lung structures (RB-right Bronchus, 
LB- Left Bronchus, LV- Left Ventricle and tumor. C) Depiction of microspheres lodging in the 
bronchial circulation of the lung and tumor. Right mainstem bronchus (RB) and Left mainstem 
bronchus (LB) can be visualized with systemic microspheres lodging in bronchial arteries 
(indicated by red arrows).  Systemic microspheres can also be seen lodged in the descending aorta 
(A) and esophagus (E). D) Depiction of microspheres lodging in the pulmonary capillaries of the 


















 Previous studies describing the pro-angiogenic phenotype of the bronchial artery 
in lung disease begged the question of its role in lung tumor perfusion. While there are 
conflicting reports suggesting each circulations involvement in tumor growth (66, 67, 
130), the goals of this study were to address this question using a functional measurement 
of quantifying tumor perfusion in the newly developed model of NSCLC. The use of 
fluorescent microsphere injection for quantification of angiogenesis was previously used 
in our lab in a model of pulmonary ischemia (64, 132, 133).  Adapting the protocol to 
include two different colored microspheres and two injection sites in an already 
established method that allowed quantification of tumor perfusion from the bronchial and 
pulmonary circulations independently.    
 When examining tumor perfusion at a wide range of tumor sizes, the total number 
of microspheres lodged in each tumor was significantly correlated with tumor size.  It is 
not surprising that tumor perfusion would increase with tumor size, and since there were 
no cases in which a tumor grew without an increase in perfusion, this correlation 
suggested that tumor growth was reliant on an increase in tumor perfusion.  Although we 
see the increase in total perfusion, it is unclear from this observation if angiogenesis is 
occurring or these tumors were growing around the existing vasculature.  
When the bronchial and pulmonary circulations were examined separately, each 
showed an increase in perfusion with tumor size. The correlation of the bronchial 
circulation with tumor weight was highly significant (p<0.0001) indicating that while 
perfusion from both circulations increased with tumor size, the bronchial circulation had 
more significant change.   Because tumor growth and increased perfusion could occur 
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without angiogenesis if the tumor was simply growing around the existing pulmonary and 
bronchial circulations, this initial examination of correlations alone was not sufficient to 
determine if angiogenesis was occurring.   
In order to better address angiogenesis of each bed, microspheres from the 
pulmonary and bronchial circulations were totaled and each circulation was assessed as a 
percentage of total tumor perfusion. In small tumors (<0.5g) the pulmonary circulation 
accounted for approximately 90% of the total tumor perfusion and significantly 
decreasing to 69% of total tumor perfusion in large tumors (>0.5g).  Subsequently, the 
bronchial circulation increased from 10% of total tumor perfusion in small tumors to 31% 
in large tumors resulting in a 227% increase in bronchial perfusion between small and 
large tumors.  While the pulmonary tumor perfusion was not changing, the percent of 
total tumor perfusion from the pulmonary circulation was decreasing coinciding with the 
increase in the percent of total tumor perfusion from the bronchial circulation. If 
angiogenesis was occurring in the pulmonary circulation equaling that of the bronchial 
circulation, the percentage of total tumor perfusion from each circulation should not 
change. Therefore, we infer that the pulmonary circulation remained unchanged and the 
bronchial circulation increased as tumor size increased.   
Visualization of fluorescent microspheres was possible by cryomicrotome 
imaging.  For the purpose of these images alone, 96% less microspheres were injected 
into the pulmonary circulation than the bronchial circulation. The resulting images depict 
a pulmonary circulation, which appears to look the same in the lung tumor as in the 
surrounding lung tissue. It is hard to distinguish in the images of the pulmonary 
circulation where the lung tissue ends and the tumor tissue begins.  The bronchial 
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circulation was also well defined in these images.  Because of OCT filling the airways it 
was easy to find the major airways and corresponding bronchial vessels where 
fluorescent microspheres were lodged.  Microspheres infused through the aorta defined 
the entire systemic vasculature, which can be depicted in small vessels branching from 
the aorta and esophagus where microspheres had lodged.  Additional bronchial vessels 
were observed sparsely throughout the lung depicted by microspheres in the lung 
parenchyma, however the majority of microspheres were lodged in the tumor vasculature.  
Though perfusion measurements were not possible from these images, the tumor tissue 
did appear to have more bronchial microspheres (42 spheres visible) in this specific 
cross-section than the right lung (27 spheres visible).  Some auto fluorescence was 
observed in the tumor throughout lung sections, however this did not interfere with 
visualization of microspheres from the bronchial circulation. These images, while not 
quantitative, confirm the data from our perfusion measurements that the bronchial 
circulation is increasing in response to tumor growth.   
In models of pulmonary ischemia and asthma (69,70) bronchial angiogenesis 
occurs throughout the airway tree.  Because of these observations, we questioned if 
bronchial artery angiogenesis was localized to only the lung tumor or the rest of the left 
lung tissue as well. There was no change in the pulmonary or bronchial circulation to the 
left lung between animals that had small or large tumors.  These data suggest that 
bronchial artery angiogenesis was occurring within the tumor.  It could be hypothesized 
that pro-angiogenic growth factors secreted by a growing lung tumor were acting locally 




While fluorescent microsphere quantification of angiogenesis has many advantages 
there were some shortcomings to this method.  With this method we assumed the 10µm 
microspheres were lodging in the capillaries of the tumor, however there was no way to 
visualize the microspheres in each animal before perfusion quantification.  Great lengths 
were taken to visualize the fluorescent microspheres in a few animals that could not be 
used for quantification.  This method also required some flexibility with tumor size since 
tumor growth rates varied between animals and a tumor could not be visualized before 
the experiment.  
3.5 Conclusion: 
 
 Tumor perfusion from the pulmonary and bronchial circulations was determined 
using two different colored fluorescent microspheres and two injection sites.  This 
method provided a functional and reproducible way of quantifying angiogenesis in vivo.  
We observed a significant correlation between total tumor perfusion and tumor size, as 
well as pulmonary and bronchial perfusion with tumor size.  The percentage of total 
tumor perfusion from the bronchial circulation significantly increased in large tumors and 
bronchial angiogenesis was specific to tumor tissue Further in vivo quantification of 
angiogenesis from the bronchial and pulmonary circulations need to be done to confirm 













 Bronchial artery angiogenesis has been implicated in several lung disease states, 
though lung tumor angiogenesis specifically from the bronchial artery is still 
controversial (63, 64, 134-137). As early as 1967, a postmortem study revealed a dual 
vascular supply in lung tumors (138). However, quantification of these vascular beds was 
not possible until more recently leading to the controversial topic of which circulation 
was primarily responsible for sustaining lung tumor growth.  
 Vascular imaging studies have increased in popularity because of their value in 
diagnosis and determining the effectiveness of angiogenesis inhibiting drugs in both 
primary and metastatic lung cancer (139-141). Nambu and colleagues conducted a small 
study (9 patients) of hemodynamics by bronchial arteriography after thoracic irradiation 
therapy with different subtypes of lung cancer. Bronchial angiogenesis was observed in 
patients who developed radiation pneumonitis. The bronchial arteries in these patients 
were unaffected by the thoracic irradiation therapy, and subsequently bronchial artery 
infusion of anti-cancer agents was performed with excellent outcomes (142).  Yuan et al. 
recently outlined a detailed method for contrast enhanced CT scanning to quantify tumor 
perfusion.  They concluded that the bronchial circulation was dominant and tumor 
circulation was moderately dependent on tumor size (66). Complimenting this finding, 
Nguyen-Kim and colleagues also described tumor perfusion to be reliant on tumor size as 
well as histological subtype utilizing similar methods of blood flow quantification by CT 
scanning (67). While these studies advanced imaging protocols for bronchial perfusion 
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and provided information on potential vascular relationships with tumor size, the fact that 
they were performed in patients limited the ability for multiple scanning and surgical 
interventions that could be possible in an animal model.  
 Adapting HRCT scanning protocols from patient studies to animal models is 
essential for acquiring more detailed information regarded tumor vasculature/size 
relationships.  Quantification of the bronchial perfusion in Sprague Dawley rats by 
contrast enhanced micro-CT was performed to image the dual circulations of the lung 
with and without pulmonary occlusion surgery (143). In a model of hepatocellular 
carcinoma, perfusion CT scans were used to quantify hepatic perfusion index, transit 
time, liver distribution volume, and arterial and portal blood flow independently (144). 
Rat models of angiogenesis, gliomas, prostate cancer, and liver cirrhosis have all utilized 
perfusion CT imaging for hemodynamic studies (145-148).  
 In this study, we sought to confirm the increase in bronchial circulation that was 
observed by fluorescent microsphere injection by using a more refined technique of 
perfusion quantification, contrast enhanced HRCT scanning.  Given the common 
bronchial artery manipulations in patients with NSCLC, we ablated the bronchial 
circulation to confirm its essential role in lung tumor growth.   
  
   







Quantification of tumor perfusion by contrast enhanced CT imaging.  
Contrast enhanced CT imaging was used to quantify tumor perfusion from the bronchial 
and pulmonary circulations independently.  
Rats were anesthetized with a ketamine/xylazine/DiH2O (1:1:2) solution.  An incision 
was made on the medial surface of the left hind limb and tissue was dissected to expose 
the femoral vein. The vein was isolated and a catheter containing heparinized saline was 
inserted and secure in the vein. Contrast medium (Visipaque 320, GE Healthcare, Little 
Chalfont, Buckinghamshire, United Kingdom) was infused through the femoral catheter 
during HRCT scan.  
 





After the baseline scans were acquired (far left images top and bottom), repeated total 
thoracic scans were acquired while intravenous (IV) contrast medium (0.25% Visipaque) 
was injected through a femoral venous catheter. Approximately 50 images covering the 
thorax from apex to base were repeatedly acquired every 0.1 seconds during the contrast 
infusion over a total 9-second time interval.  From the repeatedly acquired thoracic scans, 
we selected 3 sets of HRCT chest scans: 1) at baseline (prior to IV contrast, far left top 
and bottom), 2) on the first pass of the IV contrast through the right heart and into the 
pulmonary circulation (middle top and bottom), and 3) after the IV contrast passed 
through the right heart, the pulmonary circulation, the left heart, and into the systemic 
circulation (far right top and bottom).  
  
On the three HRCT thoracic image sets, a Region of Interest (ROI) was drawn around the 
lung tumor perimeter on every scan where the tumor could be identified (methods fig 4, 
bottom left, middle and right).  To determine perfusion to the tumor, the mean intensity 
(HU) of the tumor was measured during IV contrast infusion.   On each of the three 
thoracic images sets, the mean intensity of the tumor ROI was calculated on each slice.  
The overall mean HU intensity for the tumor for each rat at each time point was then 
averaged over all the scans in that HRCT image set. 
  
Any increase in tumor contrast intensity during the first pass of the IV contrast through 
the right heart and the pulmonary circulation, but not yet in the left heart was considered 
due to the pulmonary circulation alone (methods fig 4, middle top).  Any increase in 
tumor intensity after the IV contrast passed through the right heart, the pulmonary 
circulation, and the left heart, was considered due to the pulmonary and the systemic 
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(bronchial) circulations (methods fig 4, right top).  In order to determine the contribution 
of the bronchial circulation alone, we subtracted the tumor contrast intensity after 
contrast passed through the right heart, the pulmonary circulation, and the left heart 
(methods fig 4, right top) from the tumor intensity after the IV contrast passed through 





Table 3: Sample calculation of ROI intensity 
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Table 3: Sample calculation of ROI intensity 
A) After the perfusion scan, images were divided into three time points: baseline, pulmonary 
circulation and bronchial circulation. A region of interested was draw around the tumor in each 
image and mean intensity for each region of interest was measured. This was repeated for every 
image that the tumor was visible (in this case 32 images).   
B) The average intensity for all 32 images was calculated for each time point (column 1). The 
intensity of the baseline perfusion was subtracted from both the pulmonary and bronchial 
perfusion time points (column 2). The intensity of the pulmonary perfusion was then subtracted 
from the bronchial perfusion time point to calculate only the intensity from the bronchial 
circulation (column 3). To normalize the values and account for any differences in the rate or 
Average Intensity 12.5995625  16.54671875  40.78315625  











intensity (784 HU) 
Baseline 12.59    
Pulmonary 16.54 3.95  0.005 
Bronchial 40.78 28.19 24.24 0.031 
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quantity of IV contrast delivered between animals or in the same animal on different days, the 
measured pixel intensities in the tumor were divided by the maximum intensity detected in the 





HRCT scanner settings: 
 Collimator: 128 x 0.6mm 
 Kernel: H70h Very Sharp 
 Effective mAs: 350 
 kV: 120 
 Scan time: 6 sec + 2 sec delay 
 Slice: 0.6 x 0.4mm 
 Time increment: 0.05 sec 
 Lung window: Width-1600 Level-500 
 Field of View: 50 mm 
            Reconstructions: Standard filtered back projection 
 
Bronchial Artery Ablation:  
To confirm the role of the bronchial artery in lung tumor growth we eliminated the left 
branch of the bronchial artery and measured tumor volume 4 weeks after ablation 
surgery.  
After an initial measurement of tumor volume by HRCT 4 weeks after adenocarcinoma 
cell injection, rats were anesthetized in 2% isoflurane with room air. The anesthetized rat 
was intubated, placed on a ventilator, and a transverse incision was made into the skin 
covering the thorax on the left side. A thoracotomy was performed between the 4th and 5th 
rib. The left lung was repositioned with forceps and the airway was exposed to visualize 
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bronchial arteries on the dorsal surface of the left main stem bronchus. Bronchial arteries 
were cauterized using a Gemini Cautery System (Braintree Scientific, Braintree, MA).  In 
sham animals, the same surgical procedure was followed, but an intercostal artery was 
cauterized instead of the bronchial artery.  The lungs were hyper-inflated to reestablish 
thoracic pressure as the thorax was closed with 4-0 suture (Myco Medical, Cary NC).  
Sensorcaine (Bupivacaine 2mg/kg) was injected at the site of the incision for analgesia 
and the incision was closed with methyl acrylamide adhesive.  The rats were allowed to 
recover on the ventilator breathing room air (5-10 breaths/minutes), then were extubated 
and returned to their cages.  
 
Validation of contrast enhanced CT imaging in established model of bronchial 
angiogenesis: 
Quantifying the bronchial circulation by contrast enhanced HRCT scan was performed in 
an established model of bronchial angiogenesis to validate scanning measurements. All 
protocols were approved by the Johns Hopkins and Washington University Animal Care 
and Use Committees. Male Brown Norway rats (BN, Charles River, 100 g) were 
anesthetized with 2% isoflurane and room air. Rats were then given house dust mite 
allergen (HDM, Der p 1; 50 l g/challenge, Greer Laboratories) by intranasal aspiration 
twice/week for 1, 2, or 3 weeks duration. Contrast enhanced HRCT scanning was 









Validation of perfusion quantification by contrast enhanced HRCT scanning 
 
Representative images of lungs from Naïve vs. HDM treated rats showed 
increased bronchial circulation, made visible by the infusion of contrast medium into the 
vasculature (indicated by red arrows) after HDM treatment.  Intensity (Hounsfield Units; 
HU) was measured for regions of interest including the left and right lungs then totaled 
for each image slice comprising the entire lung from apex to base.  This initial study of 7 
animals showed an increase in bronchial circulation after 1, 2 and 3 weeks of HDM 
treatments. Most important, these studies confirmed that the HRCT protocol could 
separate and quantify the pulmonary and bronchial circulations by contrast enhanced 




Increased bronchial circulation observed in HDM treated rats 
Contrast Enhanced HRCT scanning was used to quantify the bronchial circulation in HDM 
treated rats.  A) In a model that has previously shown an increase in bronchial vessels after HDM 
treatment, we confirmed that the increased bronchial vessels could be detected by contrast 
enhanced HRCT scan. Increased bronchial perfusion can be seen in representative scan from an 
animal treated with HDM for 3 weeks (indicated by red arrows). B) An increase in intensity from 
the bronchial circulation was observed by contrast enhanced HRCT scan 1,2 and 3 weeks after 








Prism Graphpad software was used to perform the statistical analyses. Linear 
regression and goodness of fit was used to calculate the correlation of tumor intensity 
(HU) with tumor weight.  A paired T-Test (two-tailed) was use to determine significance 
between perfusion to small and large tumor groups quantified by intensity.  An unpaired 
T-Test (two-tailed) was used to determine significance between the change in tumor 
volume and the final tumor volumes at 8 weeks with an intact BA or ablated BA. 







Tumor perfusion quantification by HRCT scanning 
 
We quantified tumor volume and tumor perfusion from the pulmonary and 
bronchial circulations in 11 different animals.  Tumor volumes ranged from 0.01 to 1.5 
cm3.  Tumor perfusion from the bronchial circulation was significantly correlated with 
tumor volume (r2=0.56; p=0.005) (Fig 11A). When tumors were partitioned by volume 
into groups of small tumors (<0.3cm3) versus large tumors (>0.3cm3) significantly greater 
bronchial perfusion was observed in large tumors (p<0.0001; Fig 11B). Unlike the 
bronchial circulation, there was no difference in pulmonary perfusion with tumor size 
(Fig 12A), and no change in pulmonary perfusion between small and large tumors (Fig 






Fig11: Bronchial tumor perfusion increases with tumor volume  
Bronchial tumor perfusion was determined by contrast enhanced HRCT scanning. 
A) Tumor perfusion (intensity of contrast medium Hounsfield units (HU) as a fraction of 
maximum HU [also see methods]) from the bronchial circulation was significantly correlated 
with tumor volume (r2=0.56; p=0.005; n=11). B) When tumors were partitioned by volume 














Fig 12. Pulmonary tumor perfusion does not change with tumor volume 
 Pulmonary tumor perfusion was determined by contrast enhanced HRCT scanning.  
(A) In contrast to the bronchial circulation there was no difference in pulmonary perfusion as 
measured by contrast enhanced HRCT by tumor volume, and B) When tumors were partitioned 
by volume (<0.3cm3 vs. >0.3cm3) there was no significant difference in pulmonary perfusion 










Tumor volume assessment after bronchial artery ablation 
Because we observed an increase in bronchial perfusion with tumor size, we 
examined tumor growth after the bronchial artery was ablated. Animals in which the 
bronchial artery was ablated little to no change in tumor volume occurred over 4 weeks.  
In several cases, tumor volumes decreased after ablation surgery and in a single case a 
tumor was no longer detectible by CT scan. One animal in which the bronchial artery was 
ablated (indicated by blue point) had recruited blood vessels visible by gross dissection 
from the chest wall and subsequently had an increase in tumor volume over 4 weeks (Fig 
13A). The two animals receiving a sham surgery (indicated by red points in Fig 13) had 
the largest final tumor volumes compared to animals receiving the bronchial artery 
ablation surgery.  Initial and final tumor volumes between 4 and 8 weeks after 
adenocarcinoma cell injection were calculated in animals with an intact bronchial artery 
or sham (indicated by triangles) compared to animals in which the bronchial artery was 
ablated.  Animals with intact bronchial arteries had increasing tumor volumes between 4 
and 8 weeks in contrast to the animals receiving bronchial ablation surgery that had no 
tumor growth (Fig 13B).  In the bronchial artery ablation group, there were significantly 
less changes in tumor volumes between 4 and 8 weeks (P=0.0009; Fig 14A) and 
significantly smaller final tumor volumes at 8 weeks (p=0.0076; Fig 14B) compared to 







Fig 13: Tumor volume assessed by HRCT scan after bronchial artery ablation 
 Tumor volume was calculated weekly after bronchial artery ablation.  
A) Initial tumor volume measurements were taken by HRCT scan immediately prior to bronchial 
artery ablation surgery. Subsequent volume measurements were taken to track tumor volume for 
4 weeks after BA ablation. Sham animals (see methods; indicated by red points, n=2) had the 
largest tumor volumes 4 weeks after surgery.  Animals receiving BA ablation surgery had a 
decrease, or no change in tumor volume over 4 weeks, and one animal (indicated by blue point) 
had recruited blood vessels from the chest wall and showed an increase in tumor volume over 4 
weeks. B) Initial and final tumor volumes between 4 and 8 weeks after adenocarcinoma cell 
injection were calculated from animals with an intact BA or sham (indicated by triangles; n=8), 
compared to animals receiving bronchial artery ablation surgery (n=6).  Animals with intact BAs 
have an increase in tumor volume between 4 and 8 weeks that was not observed in animals 















Fig 14. Change in tumor volume and final tumor volumes with Intact vs. Ablated 
BA. 
Tumor volumes were assessed by HRCT scans four weeks after bronchial artery ablation.   
A) There was significantly less change in tumor volume between 4 and 8 weeks in animals with 
bronchial artery ablation (**p=0.0009). B) At 8 weeks, tumor volume were significantly 









To confirm that the bronchial artery ablation surgery did attenuate the bronchial 
circulation from lung tumors, we use contrast enhanced HRCT scanning to quantify 
tumor perfusion.  In the 6 animals that received the bronchial artery ablation, bronchial 
tumor perfusion was decreased compared to animals with intact bronchial arteries. There 
was no correlation between bronchial perfusion and tumor volume in animals after 
bronchial artery ablation, indicating that ablation was effective in diminishing bronchial 





Fig 15: Attenuation of bronchial perfusion confirmed by perfusion CT scan. 
The systemic perfusion four weeks after bronchial artery cauterization was measured by perfusion 
CT scan (represented in red). Bronchial tumor perfusion was less than normal perfusion patterns 










While previous studies using HRCT scanning to quantify the lung’s circulations 
in tumor perfusion were successful in patients, we were uncertain if this method of 
perfusion quantification could be translated to a small animal model.  Wieholt and 
colleagues successfully quantified bronchial perfusion by HRCT scanning in the rat after 
pulmonary artery obstruction where there was increased bronchial circulation (143).   
When developing a protocol for quantification of tumor perfusion by contrast enhanced 
HRCT scanning, we validated our technique in an already established model of bronchial 
angiogenesis.  
We previously quantified tumor perfusion by fluorescent microsphere injection, 
and while the data obtained was valuable, and showed a correlation between tumor size 
and bronchial perfusion, there was only an estimate of tumor size before the experiment 
took place.  The use of HRCT made it possible to monitor tumor growth longitudinally 
and quantify tumor perfusion at predetermined tumor volumes.  This refined method 
provided the ability to acquire perfusion data from a complete range of tumor volumes 
instead of estimating tumor volume based on time after adenocarcinoma cell injection, 
which was shown to vary between animals.  
With perfusion HRCT the overall change in perfusion confirmed the results 
quantified by fluorescent microsphere injection.  In small tumors, systemic bronchial 
perfusion contributed approximately 21% of total perfusion.  In large tumors, greater than 
0.3cm3 median volume, bronchial perfusion contributed approximately 79% of total 
tumor perfusion resulting in an increased average bronchial tumor perfusion of 276% 
between small and large tumors.  Despite the increase in bronchial circulation, there was 
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no change in pulmonary circulation to tumor perfusion.  While it appears that the 
pulmonary circulation decreases from small to large tumors, the results were not 
significant, suggesting that pulmonary circulation is not correlated with tumor size and 
does not increase as tumor size increases.   
 While the percentages of tumor perfusion contributed between small and large 
tumors from the bronchial circulation were much lower when measured by fluorescent 
microsphere injection (~10% in small vs. 30% of total tumor perfusion in large tumors) 
the magnitude of average increase in bronchial perfusion between small and large tumors 
(206% vs. 276%) was quite similar. Differences in magnitude of the initial perfusion with 
the two methods can likely be attributed to the different tumor sizing methods (weight vs. 
calculated volume) and different median tumor sizes for the analysis. Importantly, both 
perfusion measurements demonstrated that the bronchial circulation increased with tumor 
size and the pulmonary circulation remained relatively constant and did not increase with 
tumor size. These functional results demonstrate that the bronchial circulation undergoes 
angiogenesis to support the needs of the growing lung tumor over the course of 8 weeks, 
while the pulmonary vasculature remains unchanged.   
Beginning in 1969, bronchial artery infusion therapy was used as a route for more 
direct delivery of chemotherapy to lung tumors in patients with lung cancer (149).  Such 
approaches to treat NSCLC and hepatocellular carcinoma lung metastases are still being 
used (150, 151).  It is also common for patients with NSCLC to experience life-
threatening hemoptysis, and for decades it has been routine practice to embolize small 
branches of the bronchial artery as an effective treatment (152, 153).  In cases where 
bronchial artery embolization has been performed, there have been no reports on how this 
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procedure specifically alters tumor growth. Since only small branches of the bronchial 
artery are typically embolized and patients generally are also undergoing chemotherapy, 
results of embolization on lung tumor growth have not been established.   
To further confirm the critical role of bronchial angiogenesis in tumor growth, we 
surgically intervened and studied subsequent tumor growth after the elimination of the 
bronchial circulation.  After 4 weeks of tumor growth, the left bronchial artery was 
cauterized.  After this ablation, we observed small changes in tumor volume in weekly, or 
biweekly measurements of tumor growth. While growth rates between animals varied 
slightly there was no overall change in tumor volume for at least 4 weeks after the 
surgical intervention.  Final tumor volumes at 8 weeks were significantly smaller than the 
8 week tumor volumes in animals with an intact bronchial artery.  Perfusion 
measurements made at the corresponding 8 week tumor volume determination confirmed 
the continued absence of any new systemic blood flow, as determined by the significant 
decrease in the both the baseline and slope of the relationship between bronchial 
perfusion and tumor size.  
In this study, we integrated imaging protocols for quantifying lung tumor 
perfusion typically found in patient studies and adapted them for a model of NSCLC in 
the rat.  Our data compliments patient findings that tumor perfusion from the bronchial 
circulation is dependent on tumor size, but given the use of an animal model we had the 
ability to track tumor volume before perfusion measurements to depict a more complete 
tumor volume/perfusion relationship than was observed in patient studies.  The animal 
model also afforded us the ability to surgically ablate the bronchial circulation and 
continually track tumor growth after surgery.  A decrease in tumor growth and final 
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tumor volumes suggested the essential role of bronchial artery angiogenesis in lung tumor 




From contrast enhanced HRCT scanning we observed an increase in tumor 
perfusion from the bronchial circulation that correlated with tumor size.  There was no 
change in tumor perfusion from the pulmonary circulation. Because of the inhibition of 
tumor growth after bronchial artery ablation, we concluded that angiogenesis of the 
bronchial circulation was critical for tumor growth.  Without new blood vessels supplied 
by the systemic bronchial vasculature, lung tumors could not grow beyond a minimal size 











 Angiogenesis promoting tumor growth in the lung is unique because of the dual 
circulations responsible for tumor perfusion.  Studying the ability of each circulation to 
undergo angiogenesis individually, in the context of tumor growth, provides new 
potential for the discovery of new drug therapies that can specifically target a single 
vasculature therefore eliminating global side effects typically seen from current anti-
angiogenic drugs.  A better understanding of the mechanisms of angiogenesis, and how 
endothelial cells from the pulmonary and bronchial circulations differ in their angiogenic 
phenotype, is the first step to understanding lung tumor angiogenesis.  
 Angiogenesis can occur through both sprouting and non-sprouting processes (29).  
Sprouting angiogenesis involve the formation of new capillaries from pre-existing vessels 
beginning with angiogenic stimuli, the most common being vascular endothelial growth 
factor (VEGF). The responsiveness of an endothelial cell is dictated by levels of VEGF 
receptor activation and NOTCH signaling in response to a VEGF gradient (154).  In 
addition to cellular activation, VEGF is responsible for cell migration, vessel dilation, 
and permeability (155). After a VEGF gradient is established to guide endothelial 
sprouting, the local extracellular matrix is degraded to allow for endothelial cell 
migration.  Proliferation of endothelial cells, at the branching end of the migration 
column, begin to elongate and organize into three dimensional tubes eventually forming a 
new capillary lumen (29).  VEGF, Interleukin-8 (IL-8), basic fibroblast growth factor 
(bFGF), angiopoietins, and matrix metalloproteinases (MMPs) tightly regulate the 
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process of endothelial sprouting through matrix degradation and endothelial cell 
stimulation (156).   Non-sprouting angiogenesis involves the enlargement, splitting and 
fusion of pre-existing vessels relying on endothelial proliferation within the vessel walls. 
Both sprouting and non-sprouting angiogenesis have been shown to be involved in tumor 
angiogenesis (157).   
 In addition to the complex role of VEGF in vessel sprouting, Interleukin-8 (IL-8) 
has been shown to play a large role in regulating angiogenesis.  IL-8 is a CXC 
chemokine, which are ELR+ (glutamic acid, leucine, arginine) that can be stored in 
endothelial cells or secreted by macrophages and mediates immune responses through its 
powerful chemoattractant properties.  IL-8 is responsible for endothelial cell 
proliferation, capillary tube formation, and MMP production (158). The silencing of IL-8 
and the blocking of its receptor (CXCR2) has led to the inhibition of angiogenesis (132, 
159).   
Because lung tumors have been shown to use several methods of vascularization 
outside of vessel sprouting, including vasculogenesis, vessel co-option, and vasculogenic 
mimicry, it is reasonable to suggest that tumor vascularization could be dictated by the 
innate properties of each circulation. The innate properties of each circulation’s ability to 
undergo angiogenesis are a direct representation of the endothelial cells in each vascular 
bed. Examining heterogeneity between endothelial cells of the pulmonary and bronchial 
circulation could explain the differences between each circulation’s responses to lung 
tumor growth.   
Endothelial cells have shown great heterogeneity between organ systems, vascular 
beds within an organ system, and even cells within the same region of a single vascular 
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bed (160). Endothelial cells are responsible for vessel permeability, leukocyte trafficking, 
vasomotor tone and angiogenesis. The structure of endothelium lining capillaries can be 
continuous, fenestrated, or discontinuous depending on the function of that specific 
vascular bed (160).  A continuous endothelium, as in the lung, is responsible for tightly 
regulating permeability and transport of fluids and solutes across cell barriers, while a 
fenestrated endothelium can be found in the kidneys where filtration and secretion occur 
(161, 162).  
Several studies have investigated differences in the endothelium of the pulmonary 
circulation (170). The endothelium of the pulmonary circulation contrasts greatly 
between the large pulmonary artery, smaller arterioles, and the microvasculature (171).  
Differences between the endothelium’s role in barrier function between sections of the 
pulmonary circulation have been of great interest given the vital role of barrier function 
in maintain efficient gas exchange.  Microarray analysis revealed differential gene 
expression of cellular adhesion molecules in microvascular endothelial cells compared to 
pulmonary artery endothelial cells contributing to highly regulated tight junctions and 
decreased permeability (172, 173). Differences in leukocyte trafficking, expression of 
calcium channels and cell surface markers have been observed between endothelial cells 
of the pulmonary artery and microvasculature (174, 175). While heterogeneity of the 
endothelium in the pulmonary circulation has been examined, little is known about the 
bronchial endothelium responses relative to the pulmonary endothelium.  
In this study we examined endothelial cell heterogeneity specifically as it relates 
to angiogenesis. Through assays of proliferation, chemotaxis and tube formation we 
quantified the angiogenic potential of endothelial cells from the bronchial artery, 
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pulmonary artery and pulmonary microvasculature in their response to angiogenic 
stimuli.  By examining the innate differences in the angiogenic phenotype of each 
endothelial cell type we obtained a better understanding of the differences between the 




PCR Array: Left lung, right lung, and lung tumors were collected and rapidly frozen in 
liquid nitrogen from naïve rats, and 1, 4 and 9 weeks after adenocarcinoma cell injection.  
RNA was isolated from tissue according to the RNeasy mini kit protocol (Qiagen, Hilden 
Germany). All samples were run in Angiogenesis RT2 Profiler PCR Arrays (Qiagen; 
http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-024A.html) for both rat and 
human. Array included:  
 
Angiogenic Factors: 
Growth Factors and Receptors: Angpt1 (Agpt), Bai1, Col18a1, Ctgf, Ereg, Fgf1, Fgf2, 
Fgf6, Fgf16, Fgfr3, Figf (Vegf-d), Flt1, Fzd5, Itgav, Jag1, Kdr, Nrp1, Pgf, Tek, Vegfa, 
Vegfb, Vegfc. 
Adhesion Molecules: Col18a1, Ctgf, Eng, Itga5, Itgav, Nrp1, Tek. 
Proteases, Inhibitors and Other Matrix Proteins: Anpep, Col4a3, Fn1, Mmp19, Serpinb5, 
Serpinf1. 
Transcription Factors and Others: Angpt2 (Agpt2), Epas1, Mapk14, Tbx4. 
 
Other Factors Involved in Angiogenesis: 
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Cytokines and Chemokines: Ccl2, Cxcl1 (GRO), Cxcl2 (GRO2), Cxcl9, Ifna1, Ifnb1, 
Ifng, Il1b, Il6, Tnf. 
Other Growth Factors and Receptors: S1pr1, Efna5, Egf, Hgf, Igf1, Itgb3, Lep, Mdk, 
Npr1, Nrp2, Pdgfa, Pdgfb, Tgfa, Tgfb1, Tgfb2, Tgfb3, Tgfbr1. 
Adhesion Molecules: Cdh5, Itgb3, Lama5, Nrp2, Pecam1, Thbs4. 
Proteases, Inhibitors and Other Matrix Proteins: Tymp, F2 (CF-2), Mmp2, Mmp3, 
Mmp9, Plau, Plg, Timp1, Timp2, Timp3. 
Transcription Factors and Others: Akt1, Efna1 (Ephrin A1), Efna2, Hif1a, Id1, Id3, 
Lect1, Ptgs1, Sphk1 
Endothelial Cell Isolation:  
Bronchial artery, pulmonary artery, femoral artery and aorta were dissected from RNU 
nude rats.  Arteries were washed in DMEM and antibiotics, cut in 0.5mm pieces and 
placed in growth factor reduced matrigel (Corning Life Sciences, Tewksbury, MA) 
coated 24 well dishes, lumen side down. Tissue sections were incubated for 20minutes 
before media (20%FBS and Endothelial Cell Growth Supplement, EMD Millipore, 
Darmstadt, Germany) was added to wells. Tissue was removed after 5 days of culture and 
cells were allowed to grow until confluent in well.  Cells were trypsinized and cultured in 
T25 flasks until confluent at which point they were purified by using a Biotin Selection 
Kit (Stemcell Technologies, Vancouver, BC). Biotinylated tomato Lectin (Vector 
Laboratories, Burlingame, CA) was used for positive endothelial cell selection (176, 177) 
and cells were purified using magnetic nanoparticles (Stemcell Technologies) according 
to the manufacturer’s protocol.  Pure populations of endothelial cells were cultured on 
T25 flasks and angiogenic potential was measured between passages 3 and 6. In all 
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subsequent experiments, samples were run in triplicates for cells from each animal. Cell 
lines were isolated from 6 different animals, and samples from each animal were run in 
triplicate for each in vitro determination of angiogenesis (n=6).   
 
 
Pulmonary microvasculature endothelial cell isolation:  Lungs were dissected from 
RNU nude rats and sections from peripheral lung parenchyma, devoid of large vessels, 
were cut from remaining lung tissue.  Tissue was minced and incubated with 1% 
collagenase (Worthington, Lakewood, NJ) and incubated at 37oC for 15minutes.  Red 
blood cells were removed using 3ml ACK lysing buffer (Quality Biological, 
Gaithersburg, MD) for 5 min on ice. Cells were collected and washed thoroughly with 
cold DMEM and cultured on T25 flasks coated in 0.2% gelatin.  Endothelial cells were 
purified as previously described.  
 
Stimuli used for in vitro angiogenic assays: 
To determine the angiogenic potential of each endothelial cell type, in vitro cultures were 
treated with three different angiogenic stimuli. Recombinant human VEGF (R&D 
systems, Minneapolis, MN) was used in 10 and 100ng/ml concentrations. Rat 
CINC3/CXCL2, Cytokine-Induced Neutrophil Chemoattractant-3 (R&D systems, 
Minneapolis, MN) was also used in 10 and 100ng/ml concentrations as stimulus. A 
confluent T75 flask of adenocarcinoma cells were incubated for 24 hours with 10% FBS 
to yield the adenocarcinoma supernatant used as the third angiogenic stimuli for in vitro 




 Fluorescence-activated Cell Sorting (FACS) analysis of cultured cells for 
proliferation:  
To determine differences in proliferation between endothelial cell types we used Ki67 
intracellular staining, an antigen found exclusively in the nucleus during interphase, as an 
indication of cell proliferation.  
 
 Endothelial cells grown in culture (5x103) isolated from the bronchial artery, pulmonary 
artery, and pulmonary microvasculature were seeded in triplicate on 12 well dishes 
coated in 0.2% gelatin. Cells were incubated with angiogenic stimuli: rhVEGF, CINC3 
and adenocarcinoma culture supernatant. Cells were trypsinized, washed in cold DMEM, 
and stained for FACS analysis of proliferation.  Cells were incubated with endothelial 
cell marker, FITC conjugated Tomato Lectin (Lycopersicon esculentum, Sigma-Aldrich) 
for 30minutes on ice, washed and stained for live cell selection using VIVID (Invitrogen, 
Grand Island, NY).  For cell proliferation marker, cells were incubated with 
Fixation/Permeabilization buffer (Ebiosciences, San Diego CA) for 30minutes on ice, 
then washed and incubated with Ki67 (PE, BD Pharmingen, San Jose, CA). Cell counts 
were acquired on a BD FACSaria (BD, San Jose, CA). Data was analyzed with FlowJo 
Software (Tree Star, Ashland, OR).    
 
Chemotaxis Assay:  
To determine the potential for each endothelial cell type to move toward an angiogenic 




Chemotaxis to angiogenic stimuli: rhVEGF, CINC3 and adenocarcinoma culture 
supernatant, was determined using transwell, 12 well plates (6.5mm diameter inserts, 
5.0μm pore size polycarbonate transwell membrane, Corning Incorporated, Corning, 
NY).  5x103 endothelial cells from in vitro cultures of the bronchial artery, pulmonary 
artery and pulmonary microvasculature were cultured in triplicate on upper chamber of 
transwell inserts in 2% FBS, while stimulus was added to lower chamber. Cultures were 
incubated for 24hours. Transwell inserts were removed and remaining cells in lower 
chamber were counted using a hemocytometer.   
 
Tube Formation Assay:  
To determine the differences between endothelial cell types in their ability to form tubes 
in response to angiogenic stimuli, we cultured cells in 3D matrigel conditions and 
quantified the total tube lengths of cells in culture.  
 
Endothelial cells from the bronchial artery, pulmonary artery and pulmonary 
microvasculature were cultured in 12 well dishes coated with growth factor reduced 
matrigel. 5x104 cells were added to 3 wells/ cell type in DMEM with 2% FBS.  Tube 
formation in the presence of angiogenic was determined 24 hours after cells had been 
cultured. 3 representative images of each well were obtained (Olympus IX51 microscope, 
Olympus, Center Valley, PA and High Performance SensiCam, Cooke, Auburn Hills, 
MI) and tube lengths per image were measured (indicated by red arrows; methods Fig 6).  
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Total tube lengths of connecting cells were measured by use of Image Pro Plus 5.1 
software (Media Cybernetics, Bethesda, MD).  
 




Prism Graphpad software was used to calculate statistics. A One-way ANOVA 
with Bonferroni’s adjustment for multiple comparisons was used to calculate the 
significance between endothelial cell types for proliferation, chemotaxis, and tube 








Survey of angiogenic factors involved in lung tumor angiogenesis by PCR array  
 
A PCR array was used to determine the gene expression of proteins related to 
angiogenesis in both the tumor and lung tissue 2, 4 and 9 weeks after adenocarcinoma 
cell injection.  While this was a survey of proteins involved in angiogenesis in a limited 
sample size, in general there was an increase in gene expression of the left lung tissue 4 
weeks after adenocarcinoma cell injection that was not observed at 9 weeks.  This 
included proteins responsible for degrading the extracellular matrix during angiogenesis: 
(MMP 2, 9, 19, 14), PLAU (Urokinase-type plasminogen activator), and Alanyl 
Membrane Aminopeptidase (Anpep). Tumor associated membrane protein (TMP) 
responsible for endothelial membrane disruption, and Fibronectin1 (FN1) involved in the 
remodeling of extracellular matrix were also increased at only 4 weeks (Table 1).  In 
addition to extracellular matrix related proteins, the vast majority of angiogenic growth 
factors were increased at only at 4 weeks including VEGF A, B and VEGF receptors, 
transforming growth factor (TGF) alpha and beta, and fibroblast growth factor (FGF) 





Table 4: Survey of matrix degrading enzymes of rat left lung tissue  
Gene expression of extracellular matrix proteins involved in angiogenesis showed an increase in 
matrix degrading proteins at 4 weeks after adenocarcinoma cell injection compared to naïve left 






Table 5:PCR array of angiogenic growth factors in the left lung 
Gene expression of angiogenic growth factors from rat left lung tissue were increased at 4 weeks 











 Different patterns of gene expression were observed when examining the 
angiogenesis related proteins in tumor tissue. The four growth factors with the highest 
gene expression were Interleukin8 (IL-8), VEGFB, TGFB-1 and tumor-homing peptide 
F3. Matrix degrading proteins had decreased gene expression, small increases in gene 




Table 6: Survey of angiogenic growth factors in human tumor tissue 
Gene expression of angiogenic growth factors from tumor tissue was increased at 4 and 9 weeks 
after adenocarcinoma cell injection. The biggest increases were observed in IL-8, F3, and 








Determining angiogenic potential of endothelial cells 
 After determining which growth factors had the highest gene expression in tumor 
tissue, we examined the endothelial cells from each vascular bed individually.  We 
isolated primary endothelial cells from the bronchial artery (BAEC), pulmonary artery 
(PAEC) and pulmonary microvasculature (MVEC) to determine the angiogenic potential 
of each endothelial cell type.  We first examined common surface markers used to 
identify endothelial cells to see if they were expressed on all endothelial cell types.  
CD31, a typical marker of endothelial cells was not expressed on any cell type that had 
been cultured, however it was observed on endothelial cells from tissue samples. 
Lycopersicon Esculentum (Tomato Lectin) was expressed in nearly 100% of cells in all 
cell types and thus used as the primary marker of endothelial cells for histological 
imaging and proliferation experiments.  
 Because we had observed an increase in IL-8 and VEGF in tumor tissue, we used 
VEGF, CINC-3 (the rat homolog of IL-8) and adenocarcinoma supernatant, in in vitro 
assays of angiogenesis. We measured endothelial cell proliferation by FACS analysis.  As 
a positive control 20% FBS was used to stimulate endothelial cells, showing no 
significant difference in proliferation between cell types.  When stimulated by 
adenocarcinoma supernatant, there was a significant increase in proliferation in only 
BAECs (p<0.0001; Fig 16B).  After stimulation with CINC-3 at both 10 and 100ng/ml 
concentrations, there was a significant increase in proliferation of BAECs when 
compared to PAECs and MVECs (10ng/ml, p<0.05, 100ng/ml, p<0.001; Fig 16C).  
Similarly, stimulation with recombinant VEGF resulted in a significant increase in 
proliferation in BAECs (10ng/ml; BAEC vs. MVEC p<0.05, 100ng/ml; p<0.001; Fig 
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Figure 16: Cell proliferation of BAECs, PAECs, and MVECs was determined by 
FACS analysis in response to 20% fetal bovine serum, adenocarcinoma 
supernatant, CINC-3, and VEGF.  
A) When 20% FBS was used as a positive control, there was no significant difference in 
proliferation between cell types (n=6). B) After stimulation with adenocarcinoma supernatant, 
there was a significant increase in proliferation of BAECs when compared to PAECs and MVECs 
(***p<0.0001,n=6). C) Stimulation with CINC-3 at both 10ng/ml and 100ng/ml concentrations 
resulted in a significant increase in proliferation from BAECs when compared to PAECs and 
MVECs (10ng/ml; *p<0.05. 100ng/ml; **p<0.001, ***p<0.0001, n=6). D) Stimulation with 
recombinant VEGF at 10ng/ml resulted in a significant increase in proliferation of BAECs 
compared to MVECs (*p=. 02,n=6). At 100ng/ml there was a significant increase in proliferation 










Next, the ability for each endothelial cell type to migrate towards an angiogenic stimulus 
was quantified. When stimulated with adenocarcinoma supernatant there was a 
significant increase in chemotaxis from BAECs compared to PAECs (p=0.03; Fig17A).  
After stimulation with CINC-3 we observed a significant increase in both BAECs and 
MVECs compared to PAECs and 10ng/ml (BAEC vs. PAEC p<0.001, MVEC vs. PAEC 
p<0.05) and 100ng/ml concentrations (BAEC vs. PAEC p<0.0001, MVEC vs. PAEC 
p<0.0001; Fig 17B).  Upon stimulation with recombinant VEGF there was no significant 
difference in chemotaxis between any of the cells types at either 10ng/ml or 100ng/ml 




Figure 17: Cell chemotaxis of BAECs, PAECs, and MVECs, determined by 
transwell migration assay, in response to adenocarcinoma supernatant, CINC-3, 
and VEGF. 
A) There was a significant increase in chemotaxis from BAECs compared to PAECs when 
stimulated by adenocarcinoma supernatant (*p=0.03, n=6). B) When stimulated by CINC-3 there 
was a significant increase in chemotaxis of BAECs and MVECs when compared to PAECs at 
both 10ng/ml (**p<0.001, *p<. 05) and 100ng/ml (***p<0.0001, **p<0.001) concentrations 
(n=6). 
C) There was no significant difference in chemotaxis between cell types when stimulated by 









A tube formation assay was used to quantify the ability of endothelial cells from 
each vascular bed to elongate and connect to adjacent endothelial cells when stimulated 
with adenocarcinoma supernatant, CINC-3, and VEGF.  When cells were stimulated with 
adenocarcinoma supernatant, BAECs had a significant increase in total tube lengths when 
compared to PAECs and MVECs (BAEC vs. PAEC p<0.0001, BAEC vs. MVEC 
p<0.001; Fig 18A).  After CINC-3 stimulation MVECs had the greatest total tube lengths 
overall, with a significant increase from PAECs (p<0.001; Fig 18B).  When stimulated 
with VEGF, BAECs had a significant increase in total tube lengths compared to PAECs 





Figure 18: Tube formation of BAECs, PAECs, and MVECs, quantified by total tube 
lengths in tube formation assay, in response to adenocarcinoma supernatant, CINC-
3, and VEGF. 
A) When exposed to adenocarcinoma supernatant there was a significant increase in total tube 
lengths of BAECs when compared to PAECs and MVECs (***p<0.0001, **p<0.001,n=6) 
B) After stimulation with CINC-3 there was a significant increase in total tube lengths of MVECs 
compared to PAECs (**p<0.001,n=6). C) In response to recombinant VEGF there was a 
significant increase in total tube lengths of BAECs compared to PAECS and MVECs 









After observing an increase in bronchial circulation with tumor growth, we 
questioned which growth factors in both the lung tissue and tumor were involved in 
bronchial artery angiogenesis. Gene expression for the left lung was assessed by an 
angiogenesis RT2 Profiler PCR Array designed for rat tissue and gene expression was 
calculated relative to naïve left lung tissue from a nude rat.  While this experiment was 
just a survey of potential growth factors involved in angiogenesis, the most interesting 
observation was the time course at which the majority of pro-angiogenic growth factors 
were increasing in the left lung tissue. 23 of 39 growth factors and their receptors that 
were measured in this array were significantly up-regulated (greater than 2 fold increase 
in gene expression) at 4 weeks followed by drop in expression at 9 weeks.  From the 
increase in angiogenic growth factor gene expression at 4 weeks coinciding with the up-
regulation of matrix degrading enzymes in the surrounding tissue, it was possible that the 
tissue surrounding the tumor was primed by the tumor for neovascularization.    
Gene expression of tumor tissue was assed by an angiogenesis RT2 Profiler PCR 
Array designed for human tissue. When analyzing tumor tissue, relative gene expression 
from tumors 2,4 and 9 weeks after adenocarcinoma cell injection were compared to gene 
expression of adenocarcinoma cells in culture. The peak of growth factor expression 
observed at 4 weeks in lung tissue was not observed in tumor tissue. Overall only 16 
genes out of the 39 measured had a significant increase in gene expression. Several 
proteins involved in matrix remodeling had increased gene expression (COL18A1, 
COL4A3, PLAU) with a large decrease in gene expression of matrix degrading proteins 
(MMP14, MMP12). The largest increases in gene expression were observed in IL-8, 
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VEGF B, and F3.  F3 is a tumor-homing peptide that binds to endothelial cells and tumor 
cells through its receptor Nucleolin.  It also binds to endothelial progenitor cells and is a 
useful marker for angiogenesis (178). Because we observed an increase in the bronchial 
circulation in large tumors, we can hypothesize that these growth factors are important 
for bronchial artery angiogenesis.  
Along with F3, IL-8 (4wk: 93 fold increase, 9wk: 59 fold increase) and VEGF B 
(4wk: 25 fold increase, 9wk: 44 fold increase) had the highest gene expression relative to 
control adenocarcinoma cells.  While VEGF A is thought to play a large role in the 
growth of new blood vessels, we did not observe an increase in gene expression in the 
tumor tissue. VEGF B however, which has shown to be critical in maintaining the new 
blood vessels (179) was significantly increased at 2, 4 and 9 weeks after adenocarcinoma 
cell injection. Because of these results, and the literature supporting their critical role in 
angiogenesis, we used recombinant human VEGF and the counterpart of IL-8 in the rat 
(CINC-3) for stimulation for in vitro determinations of angiogenesis.  
 Because the differences in each circulation’s ability to undergo angiogenesis 
could in part be due to the innate differences in endothelial cells from each vasculature, 
we sought to determine the angiogenic potential of endothelial cells isolated from the 
bronchial artery (BAEC), pulmonary artery (PAEC) and pulmonary microvasculature 
(MVEC).  Angiogenic potential was determined by quantifying the ability of each cell 
type to proliferate, move toward angiogenic stimuli, and elongate and connect to adjacent 
cells (form tubes) in response to adenocarcinoma supernatant, CINC-3, and VEGF.  
Endothelial cell proliferation, elongation and connection to other endothelial cells, 
and movement toward angiogenic stimuli are necessary steps in the process of 
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angiogenesis (180). When examining endothelial cells these methods are frequently used 
as indications of angiogenesis (181-183). FACS analysis of proliferation in all endothelial 
cell types showed a significant increase in BAECs compared to PAECs and MVECs after 
stimulation with adenocarcinoma supernatant, CINC-3, and VEGF when normalized to 
basal levels of proliferation.  
When chemotaxis was quantified, MVECs and BAECs both showed an increased 
response to adenocarcinoma supernatant and CINC-3 compared to PAECs. 
Quantification of tube lengths showed a unique increase in tube formation in BAECs in 
response to VEGF and adenocarcinoma supernatant.  However, MVECs responded 
robustly to CINC-3 stimulation in their ability to form tubes.  When assessing all of the in 
vitro data together, it is clear that BAECs have the greatest angiogenic potential to the 
three stimuli tested. MVECs seem to have a more specific affinity of CINC-3 made 
evident by the increase in chemotaxis and tube formation upon CINC-3 stimulation.  
Since there was no increase in MVEC proliferation in response to adenocarcinoma 
supernatant, VEGF, or CINC-3, perhaps MVECs are more likely to rearrange and 
remodel than to undergo angiogenesis.   
When performing angiogenic assays it is common practice to purchase cell lines, 
most commonly human umbilical vascular endothelial cells (HUVEcs), and pulmonary 
artery endothelial cells as a model of angiogenesis in the lung.  Unfortunately, as was 
shown above, each endothelial cell type has its own unique angiogenic potential, and 
using purchased HUVEC and PAECS for in vitro angiogenic assays could be misleading. 
Previous studies have extensively examined heterogeneity among endothelial cells from 
the pulmonary artery, pulmonary microvascular and aortic endothelial cells. However, 
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this study includes endothelial cells isolated from the bronchial artery providing a better 
representation of the lungs endothelium. The angiogenic phenotype of endothelial cells 
rely heavily on their extracellular matrix cues, therefore there is always some question if 
the cells maintain their phenotype when grown in culture. Because of this we sought to 
confirm our observations of a highly angiogenic bronchial circulation both in vivo and in 
vitro.  
Further studies into the mechanisms by which the bronchial circulation responds 
uniquely to angiogenic stimuli could be valuable in the discovery of novel therapeutic 
targets.  Differences in in vivo extracellular matrix among BAECs, PAECs and MVECs 
could contribute to innate differences in proliferation. BAECs could have increased 
receptors for VEGF (VEGFR1/2) and CINC-3 (CXCR1/2), and may be more 
metabolically active than the other cell types contributing to their increased proliferative 
response to those angiogenic stimuli. If surface markers differ on the bronchial artery 
endothelium versus the rest of the lung endothelium, vascular disrupting agents and anti-
angiogenic therapies could be targeted specially to the bronchial circulation to avoid the 
unfavorable side effects seen when these therapy options are used globally.  Differences 
in cellular metabolism should also be measured in these endothelial cell types. Targeting 
metabolic enzymes like glucose transporters, hexokinase or pyruvate kinase could affect 




The results of the in vitro determinations of angiogenesis complement the in vivo 
observations depicting a pro-angiogenic bronchial circulation.  Under all conditions the 
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BAECs had a robust response to angiogenic stimuli with significant increases in 
proliferation, chemotaxis and tube formation compared to MVECs and PAECs. Further 
research on targeting the endothelium of the bronchial circulation uniquely could lead to 

















 Lung cancer is the leading cause of cancer related deaths in the United States. The 
lack of effective angiogenesis-inhibiting drugs creates challenges in increasing life 
expectancy.  Understanding the nuances of lung tumor angiogenesis is essential for the 
development of more effective therapeutic options.  In this study, we sought to develop a 
physiologically relevant in vivo model of NSCLC.  We quantified lung tumor 
angiogenesis from the bronchial and pulmonary circulations independently and their 
contribution to lung tumor growth. Finally, we examined the angiogenic potential of 
endothelial cells isolated from the pulmonary and bronchial circulations.  
 The development of a physiologically relevant animal model was critical for the 
study of lung tumor angiogenesis. It was essential for the xenograft to be injected into the 
lung of an animal with an established bronchial circulation.  Injecting adenocarcinoma 
cells directly into the left lung of a nude rat resulted in the formation of a single, well-
vascularized tumor. After adenocarcinoma cell injection we observed a non-linear 
increase in tumor size over the course of 8 weeks. By histological examination we 
confirmed the pathological phenotype of adenocarcinomas typically seen in patients.   
Developing this model of NSCLC allowed us to independently examine the bronchial and 
pulmonary circulation’s ability to support tumor growth.   
 In the first method for quantification of tumor perfusion, fluorescent microsphere 
injection was used with two different colored microspheres and two injection sites to 
quantify tumor perfusion from the bronchial and pulmonary circulations independently. 
We observed an increase in total tumor perfusion correlated with tumor size, and an 
increase in the percent of tumor perfusion from the bronchial circulation in large tumors.  
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The pulmonary circulation remained unchanged in response to tumor growth.  Because 
this method of tumor perfusion quantification did not allow tumor visualization, a more 
sensitive approach where tumor size could be tracked longitudinally was ideal.   
 In the second method for quantification of tumor perfusion contrast enhanced 
HRCT scanning was used for independent measurements of tumor perfusion from the 
bronchial and pulmonary circulations.  Bronchial perfusion was correlated with tumor 
size with an increased bronchial perfusion to large tumors compared to small tumors.  
Consistent with previous observations, the pulmonary circulation remained unchanged in 
response to tumor growth.  
After confirming by two methods of tumor perfusion quantification that there was 
an increase in the bronchial circulation with tumor volume, we ablated the bronchial 
artery to confirm its significance in tumor growth. After bronchial artery ablation surgery, 
tumor growth was inhibited indicating the critical role of the bronchial circulation in lung 
tumor growth.  
 To further examine the innate differences in the pulmonary and bronchial 
circulations we isolated endothelial cells from each circulation to quantify their 
angiogenic potential.  Endothelial cells from the bronchial circulation had increased 
proliferation, chemotaxis and tube formation in response to angiogenic stimuli when 
compared to endothelial cells from the pulmonary artery and pulmonary 
microvasculature.   
In summary, as a lung tumor grows it is initially sustained primarily by the 
pulmonary circulation.  However, given the limited capacity of the pulmonary circulation 
to undergo angiogenesis, it is the bronchial circulation that must proliferate to sustain 
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tumor growth beyond the point at which a tumor can be supported by the pulmonary 
circulation alone. Given the increased angiogenic phenotype of the bronchial artery 
endothelial cells, it is reasonable to conclude that innate differences in each circulations’ 
ability to undergo angiogenesis is in part due to the angiogenic phenotype of each 
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